Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with advanced HER3-positive solid tumors

    Summary
    EudraCT number
    		 2013-001699-39
    Trial protocol
    		 NL  
    Global end of trial date
    18 Sep 2017

    Results information
    Results version number
    		 v2(current)
    This version publication date
    20 Apr 2019
    First version publication date
    15 Sep 2018
    Other versions
    		 v1
    Version creation reason

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    117158
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 -
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline
    Sponsor organisation address
    980 Great West Road, Brentford, Middlesex, United Kingdom,
    Public contact
    GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
    Scientific contact
    GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    19 Jan 2018
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    18 Sep 2017
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To determine the safety and tolerability of GSK2849330 in participants with advanced Human epidermal growth Factor Receptor 3 (HER3)-positive solid tumors.
    Protection of trial subjects
    Not applicable
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    26 Nov 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 17
    Country: Number of subjects enrolled
    Netherlands: 7
    Country: Number of subjects enrolled
    United States: 5
    Worldwide total number of subjects
    29
    EEA total number of subjects
    7
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    17
    From 65 to 84 years
    11
    85 years and over
    1

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 This is a Phase 1 study of anti-human epidermal growth factor receptor 3 (HER3) antibody, GSK2849330 in participants with advanced solid tumors expressing HER3. The study was conducted in 2 parts-Part1 (dose escalation) and Part2 (dose expansion). The starting dose in Part1 was 1.4 milligrams per kilogram (mg/kg) GSK2849330 given weekly for 28 days

    Pre-assignment
    Screening details
    		 A total of 29 participants were randomized. The study was conducted in three countries. Participants in the GSK2849330 30 mg/kg weekly arm were not double counted with any other Arm.

    Period 1
    Period 1 title
    Overall study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 GSK2849330 1.4 mg/kg weekly
    Arm description
    		 Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days
    Arm type
    		 Experimental

    Investigational medicinal product name
    GSK2849330
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

    Arm title
    		 GSK2849330 3 mg/kg every 2 weeks
    Arm description
    		 Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
    Arm type
    		 Experimental

    Investigational medicinal product name
    GSK2849330
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

    Arm title
    		 GSK2849330 3 mg/kg weekly
    Arm description
    		 Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.
    Arm type
    		 Experimental

    Investigational medicinal product name
    GSK2849330
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

    Arm title
    		 GSK2849330 10 mg/kg every 2 weeks
    Arm description
    		 Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.
    Arm type
    		 Experimental

    Investigational medicinal product name
    GSK2849330
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

    Arm title
    		 GSK2849330 30 mg/kg every 2 weeks
    Arm description
    		 Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days
    Arm type
    		 Experimental

    Investigational medicinal product name
    GSK2849330
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

    Arm title
    		 GSK2849330 30 mg/kg weekly
    Arm description
    		 Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.
    Arm type
    		 Experimental

    Investigational medicinal product name
    GSK2849330
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

    Number of subjects in period 1
    		GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Started
    1
    3
    2
    5
    4
    14
    Completed
    1
    1
    1
    2
    1
    8
    Not completed
    0
    2
    1
    3
    3
    6
         Physician decision
    -
    1
    -
    1
    1
    3
         Consent withdrawn by subject
    -
    1
    1
    -
    2
    2
         Lost to follow-up
    -
    -
    -
    2
    -
    1

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    GSK2849330 1.4 mg/kg weekly
    Reporting group description
    		 Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days

    Reporting group title
    GSK2849330 3 mg/kg every 2 weeks
    Reporting group description
    		 Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

    Reporting group title
    GSK2849330 3 mg/kg weekly
    Reporting group description
    		 Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.

    Reporting group title
    GSK2849330 10 mg/kg every 2 weeks
    Reporting group description
    		 Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

    Reporting group title
    GSK2849330 30 mg/kg every 2 weeks
    Reporting group description
    		 Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days

    Reporting group title
    GSK2849330 30 mg/kg weekly
    Reporting group description
    		 Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.

    Reporting group values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly Total
    Number of subjects
    		 1 3 2 5 4 14 29
    Age categorical
    Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan (RAP).
    Units: Subjects
        Total
    		 1 3 2 5 4 14 29
    Age continuous
    99999 indicates standard deviation for 1.4 mg/kg weekly arm could not be calculated as only a single participant was analyzed in this arm.
    Units: years
        arithmetic mean (standard deviation)
    		 63.0 ( 99999 ) 62.3 ( 4.04 ) 46.0 ( 21.21 ) 66.2 ( 7.19 ) 58.3 ( 8.73 ) 62.5 ( 11.65 ) -
    Gender categorical
    Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    Units: Subjects
        Female
    		 0 3 1 2 2 5 13
        Male
    		 1 0 1 3 2 9 16
    Race/Ethnicity, Customized
    Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    Units: Subjects
        Race customized Asian-Central/South Asian Heritage
    		 0 0 0 0 0 1 1
        Race customized White
    		 1 3 2 5 4 13 28

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    GSK2849330 1.4 mg/kg weekly
    Reporting group description
    		 Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days

    Reporting group title
    GSK2849330 3 mg/kg every 2 weeks
    Reporting group description
    		 Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

    Reporting group title
    GSK2849330 3 mg/kg weekly
    Reporting group description
    		 Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.

    Reporting group title
    GSK2849330 10 mg/kg every 2 weeks
    Reporting group description
    		 Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

    Reporting group title
    GSK2849330 30 mg/kg every 2 weeks
    Reporting group description
    		 Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days

    Reporting group title
    GSK2849330 30 mg/kg weekly
    Reporting group description
    		 Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.

    Primary: Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Parts 1 and 2 [1]
    End point description
    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; and left ventricular ejection fraction (LVEF) meeting stopping criteria. AEs were collected in All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Primary
    End point timeframe
    Median of 6.143 weeks of drug exposure
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis were performed.
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [2]
    3 [3]
    2 [4]
    5 [5]
    4 [6]
    14 [7]
    Units: Participants
        AEs
    1
    3
    2
    5
    4
    14
        SAEs
    0
    1
    0
    1
    1
    3
    Notes
    [2] - All Treated Population
    [3] - All Treated Population
    [4] - All Treated Population
    [5] - All Treated Population
    [6] - All Treated Population
    [7] - All Treated Population
    No statistical analyses for this end point

    Primary: Number of participants with dose-limiting toxicities (DLTs)-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Number of participants with dose-limiting toxicities (DLTs)-Parts 1 and 2 [8]
    End point description
    An event was considered a DLT if it occured within the first 4 weeks (28 days) of treatment, and met one of the following criteria unless it could be established that the event was unrelated to treatment: Grade 3 or greater non-hematologic toxicity; Grade 4 neutropenia lasting >5 days; Febrile neutropenia, of any grade or duration; Grade 4 thrombocytopenia, or Grade 3 thrombocytopenia associated with bleeding; Alanine aminotransferase (ALT) >3 times upper limit of normal (ULN) with bilirubin >2 times ULN; Any Grade 2 or greater toxicity that in the judgment of the investigator and GlaxoSmithKline (GSK) Medical Monitor, would be considered dose-limiting; Grade 3 or greater decrease in LVEF. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Primary
    End point timeframe
    Up to 28 days
    Notes
    [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis were performed.
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [9]
    3 [10]
    2 [11]
    5 [12]
    4 [13]
    14 [14]
    Units: Participants
        Participants
    0
    0
    0
    0
    0
    0
    Notes
    [9] - All Treated Population
    [10] - All Treated Population
    [11] - All Treated Population
    [12] - All Treated Population
    [13] - All Treated Population
    [14] - All Treated Population
    No statistical analyses for this end point

    Primary: Number of participants with grade change from Baseline in clinical chemistry data-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Number of participants with grade change from Baseline in clinical chemistry data-Parts 1 and 2 [15]
    End point description
    Blood samples were collected for analysis of following parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Total bil), calcium, creatinine, gamma glutamyl transferase (GGT), glucose, potassium, magnesium, sodium, phosphorus, uric acid. Laboratory parameters were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Baseline was defined as most recent, non-missing value from central laboratory prior to or on first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. Data for worst-case post Baseline is presented. 99999 indicates data was not available. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Primary
    End point timeframe
    Baseline and median of 6.143 weeks of drug exposure
    Notes
    [15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis were performed.
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [16]
    3 [17]
    2 [18]
    5 [19]
    4 [20]
    14 [21]
    Units: Participants
        Albumin; any Grade increase; n=1,3,2,5,4,14
    1
    1
    0
    3
    3
    6
        Albumin; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    1
        Albumin; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        ALP; any grade increase; n=1,3,2,5,4,14
    1
    0
    1
    1
    1
    7
        ALP; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    1
    1
        ALP; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        ALT; any Grade increase; n=1,3,2,5,4,14
    0
    2
    0
    2
    3
    6
        ALT; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        ALT; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        AST; any Grade increase; n=1,3,2,5,4,14
    0
    1
    0
    2
    2
    5
        AST; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    1
        AST; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Total bil; any Grade increase; n=1,3,2,5,4,14
    0
    1
    0
    1
    0
    2
        Total bil; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Total bil; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Calcium; any Grade increase; n=1,3,2,5,4,14
    0
    0
    0
    0
    2
    2
        Calcium; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    1
    0
        Calcium; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Creatinine; any Grade increase; n=1,3,2,5,4,14
    0
    1
    0
    1
    1
    2
        Creatinine; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Creatinine; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        GGT; any Grade increase; n=1,3,2,5,4,14
    1
    0
    1
    2
    3
    8
        GGT; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    1
    1
    0
    3
        GGT; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    1
    0
        Glucose; any Grade increase; n=1,3,2,5,4,14
    1
    0
    1
    3
    2
    4
        Glucose; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Glucose; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Potassium; any Grade increase; n=1,3,2,5,4,14
    0
    2
    0
    0
    0
    1
        Potassium; increase to Grade 3; n=1,3,2,5,4,14
    0
    1
    0
    0
    0
    0
        Potassium; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Magnesium; any Grade increase; n=1,3,2,5,4,14
    0
    1
    0
    0
    2
    4
        Magnesium; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Magnesium; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Sodium; any Grade increase; n=1,3,2,5,4,14
    0
    1
    0
    0
    3
    4
        Sodium; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Sodium; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Phosphorus; any Grade increase; n=1,3,2,5,4,14
    1
    0
    0
    0
    0
    4
        Phosphorus; increase to Grade 3; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Phosphorus; increase to Grade 4; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    0
        Uric acid; any Grade increase; n=0,0,0,0,0,1
    99999
    99999
    99999
    99999
    99999
    1
        Uric acid; increase to Grade 3; n=0,0,0,0,0,1
    99999
    99999
    99999
    99999
    99999
    0
        Uric acid; increase to Grade 4; n=0,0,0,0,0,1
    99999
    99999
    99999
    99999
    99999
    1
    Notes
    [16] - All Treated Population
    [17] - All Treated Population
    [18] - All Treated Population
    [19] - All Treated Population
    [20] - All Treated Population
    [21] - All Treated Population
    No statistical analyses for this end point

    Primary: Number of participants with change from Baseline in clinical chemistry data with respect to normal range-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Number of participants with change from Baseline in clinical chemistry data with respect to normal range-Parts 1 and 2 [22]
    End point description
    Blood samples were collected for analysis of following chemistry parameters: direct bilirubin (D.Bil.), cancer antigen (CA)-125, CA-15.3, CA19-9, chloride, carbon dioxide (CO2)/bicarbonate (HCO3), luteinizing hormone (LH), total protein and urea or blood urea nitrogen (BUN). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. A laboratory value that is outside the reference range was considered either high abnormal (value above upper limit of the reference range) or low abnormal (value below lower limit of the reference range). Data for worst-case post Baseline is presented. 99999 indicates data was not available. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP
    End point type
    Primary
    End point timeframe
    Baseline and median of 6.143 weeks of drug exposure
    Notes
    [22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis were performed.
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [23]
    3 [24]
    2 [25]
    5 [26]
    4 [27]
    14 [28]
    Units: Participants
        D.Bil.; Decrease to Low; n=1,3,2,5,3,14
    0
    0
    1
    0
    0
    0
        D.Bil.; increase to high; n=1,3,2,5,3,14
    0
    1
    0
    2
    1
    4
        CA-125; Decrease to Low; n=1,3,0,5,4, 0
    0
    0
    99999
    0
    0
    99999
        CA-125; increase to high; n=1,3,0,5,4, 0
    0
    0
    99999
    0
    0
    99999
        CA 15.3; Decrease to Low; n=0, 0, 0, 0, 4, 0
    99999
    99999
    99999
    99999
    0
    99999
        CA 15.3; increase to high; n=0, 0, 0, 0, 4, 0
    99999
    99999
    99999
    99999
    0
    99999
        CA 19-9.; Decrease to Low; n=1,0,0,0,2,0
    0
    99999
    99999
    99999
    0
    99999
        CA 19-9; increase to high; n=1,0,0,0,2,0
    0
    99999
    99999
    99999
    0
    99999
        Chloride; Decrease to Low; n=1,3,2,5,4,14
    0
    1
    0
    1
    2
    4
        Chloride; increase to high; n=1,3,2,5,4,14
    0
    0
    0
    0
    0
    1
        CO2/HCO3.; Decrease to Low; n=1,3,2,5,4,14
    0
    0
    0
    3
    1
    2
        CO2/HCO3; increase to high; n=1,3,2,5,4,14
    0
    1
    0
    1
    0
    7
        LH; Decrease to Low; n=1,0,2,3,2,7
    0
    99999
    0
    0
    0
    1
        LH; increase to high; n=1,0,2,3,2,7
    0
    99999
    0
    0
    0
    3
        Total Protein; Decrease to Low; n=1,3,2,5,4,14
    0
    1
    1
    1
    0
    1
        Total Protein; increase to high; n=1,3,2,5,4,14
    0
    0
    0
    1
    0
    0
        Urea/BUN; Decrease to Low; n=1,3,2,5,4,14
    0
    0
    0
    0
    1
    3
        Urea/BUN; increase to high; n=1,3,2,5,4,14
    0
    1
    1
    0
    0
    2
    Notes
    [23] - All Treated Population
    [24] - All Treated Population
    [25] - All Treated Population
    [26] - All Treated Population
    [27] - All Treated Population
    [28] - All Treated Population
    No statistical analyses for this end point

    Primary: Number of participants with grade change from Baseline in hematology data-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Number of participants with grade change from Baseline in hematology data-Parts 1 and 2 [29]
    End point description
    Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, total neutrophils, platelet count, and white blood cell (WBC). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life–threatening consequences; Grade 5: death related to AE. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. Number of participants with any grade increase, increase to Grade 3 and increase to Grade 4 in hematology data at worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Primary
    End point timeframe
    Baseline and median of 6.143 weeks of drug exposure
    Notes
    [29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis were performed.
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [30]
    3 [31]
    2 [32]
    5 [33]
    4 [34]
    14 [35]
    Units: Participants
        Hemoglobin; any Grade increase
    0
    1
    0
    0
    3
    7
        Hemoglobin; increase to Grade 3
    0
    0
    0
    0
    0
    2
        Hemoglobin; increase to Grade 4
    0
    0
    0
    0
    0
    0
        Lymphocytes; any grade increase
    0
    0
    1
    3
    1
    5
        Lymphocytes; increase to Grade 3
    0
    0
    0
    0
    0
    2
        Lymphocytes; increase to Grade 4
    0
    0
    0
    0
    0
    0
        Total neutrophils; any Grade increase
    0
    0
    0
    1
    0
    1
        Total neutrophils; increase to Grade 3
    0
    0
    0
    0
    0
    0
        Total neutrophils; increase to Grade 4
    0
    0
    0
    0
    0
    0
        Platelet; any Grade increase
    0
    1
    1
    0
    0
    0
        Platelet; increase to Grade 3
    0
    0
    0
    0
    0
    0
        Platelet; increase to Grade 4
    0
    0
    0
    0
    0
    0
        WBC; any Grade increase
    0
    1
    0
    2
    0
    1
        WBC; increase to Grade 3
    0
    0
    0
    0
    0
    0
        WBC; increase to Grade 4
    0
    0
    0
    0
    0
    0
    Notes
    [30] - All Treated Population
    [31] - All Treated Population
    [32] - All Treated Population
    [33] - All Treated Population
    [34] - All Treated Population
    [35] - All Treated Population
    No statistical analyses for this end point

    Primary: Number of participants with change from Baseline in hematology data with respect to normal range-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Number of participants with change from Baseline in hematology data with respect to normal range-Parts 1 and 2 [36]
    End point description
    Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, hematocrit, mean corpuscle hemoglobin concentration (MCHC), mean corpuscle hemoglobin (MCH), mean corpuscle volume (MCV), monocytes, red blood cell count (RBC) and reticulocytes. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as value at visit minus Baseline value. Number of participants with change from Baseline in hematology data at worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Primary
    End point timeframe
    Baseline and median of 6.143 weeks of drug exposure
    Notes
    [36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis were performed.
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [37]
    3 [38]
    2 [39]
    5 [40]
    4 [41]
    14 [42]
    Units: Participants
        Basophils: decrease to low
    0
    0
    0
    0
    0
    0
        Basophils: increase to high
    0
    0
    0
    0
    0
    0
        Eosinophils: decrease to low
    0
    0
    1
    0
    0
    0
        Eosinophils: increase to high
    0
    0
    0
    0
    0
    2
        Hematocrit: decrease to low
    0
    0
    0
    1
    1
    4
        Hematocrit: increase to high
    0
    0
    0
    0
    0
    0
        MCHC: decrease to low
    1
    0
    0
    0
    0
    3
        MCHC: increase to high
    0
    0
    0
    0
    0
    0
        MCH: decrease to low
    1
    1
    0
    0
    0
    1
        MCH: increase to high
    0
    0
    0
    0
    1
    0
        MCV: decrease to low
    0
    1
    0
    0
    0
    1
        MCV: increase to high
    0
    0
    0
    0
    0
    1
        Monocytes: decrease to low
    0
    0
    0
    0
    0
    0
        Monocytes: increase to high
    1
    0
    0
    0
    0
    2
        RBC: decrease to low
    0
    0
    0
    3
    0
    7
        RBC: increase to high
    0
    0
    0
    0
    0
    1
        Reticulocytes: decrease to low
    0
    0
    0
    1
    0
    2
        Reticulocytes: increase to high
    0
    0
    0
    1
    2
    3
    Notes
    [37] - All Treated Population
    [38] - All Treated Population
    [39] - All Treated Population
    [40] - All Treated Population
    [41] - All Treated Population
    [42] - All Treated Population
    No statistical analyses for this end point

    Primary: Number of participants with change from Baseline in urinalysis data with respect to normal range-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Number of participants with change from Baseline in urinalysis data with respect to normal range-Parts 1 and 2 [43]
    End point description
    Urine samples were collected for the analysis of urine potential of hydrogen (pH) and urine specific gravity. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. The data for worst-case post Baseline is presented. Only those participants with data available at specified time ponts were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Primary
    End point timeframe
    Baseline and median of 6.143 weeks of drug exposure
    Notes
    [43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis were performed.
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [44]
    3 [45]
    2 [46]
    5 [47]
    4 [48]
    14 [49]
    Units: Participants
        Urine pH; decrease to low; n=1, 3, 1, 5, 4, 7
    0
    0
    0
    0
    0
    0
        Urine pH; increase to high; n=1, 3, 1, 5, 4, 7
    0
    0
    0
    0
    0
    1
        Specific gravity; decrease to low; n=1,3,1,4,4,8
    0
    1
    0
    0
    0
    0
        Specific gravity; increase to high; n=1,3,1,4,4,8
    1
    0
    0
    0
    0
    0
    Notes
    [44] - All Treated Population
    [45] - All Treated Population
    [46] - All Treated Population
    [47] - All Treated Population
    [48] - All Treated Population
    [49] - All Treated Population
    No statistical analyses for this end point

    Primary: Number of participants with change from Baseline in vital signs-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Number of participants with change from Baseline in vital signs-Parts 1 and 2 [50]
    End point description
    Vital sign measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). Vital signs were graded according to NCI-CTCAE version 4.0. The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in HR (decrease to <60 beats per minute and increase to >100 beats per minute); increase in SBP from Baseline (>=120 to <140 millimeters of mercury [mmHg] Grade 1; >=140 to <160 mmHg [Grade 2]; >=160 [Grade 3]); increase in DBP from Baseline (>=80 to <90 [Grade 1]; >=90 to <100 [Grade 2]; >=100 mmHg [Grade 3]) and change in temperature from Baseline (increase to >=38 or decrease to <=35 degree Centigrade). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. The data for worst-case post Baseline is presented.
    End point type
    Primary
    End point timeframe
    Baseline and median of 6.143 weeks of drug exposure
    Notes
    [50] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis were performed.
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [51]
    3 [52]
    2 [53]
    5 [54]
    4 [55]
    14 [56]
    Units: Participants
        HR; decrease to <60 beats per minute
    1
    1
    0
    2
    0
    4
        HR; increase to >100 beats per minute
    0
    0
    1
    1
    0
    5
        Temp; decrease to <=35 degree Celsius
    0
    0
    0
    1
    0
    0
        Temp; increase to >=38 degree Celsius
    0
    0
    0
    0
    0
    4
        SBP; increase to Grade 1 (120-139 mmHg)
    0
    0
    2
    1
    2
    3
        SBP; increase to Grade 2 (140-159 mmHg)
    0
    0
    0
    1
    0
    4
        SBP; increase to Grade 3 (>=160 mmHg)
    0
    1
    0
    1
    2
    0
        DBP; increase to Grade 1 (80-89 mmHg)
    0
    1
    2
    3
    1
    7
        DBP; increase to Grade 2 (90-99 mmHg)
    0
    1
    0
    0
    0
    1
        DBP; increase to Grade 3 (>=100 mmHg)
    0
    0
    0
    1
    0
    1
    Notes
    [51] - All Treated Population
    [52] - All Treated Population
    [53] - All Treated Population
    [54] - All Treated Population
    [55] - All Treated Population
    [56] - All Treated Population
    No statistical analyses for this end point

    Primary: Number of participants with abnormal electrocardiogram (ECG) findings-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Number of participants with abnormal electrocardiogram (ECG) findings-Parts 1 and 2 [57]
    End point description
    A 12-lead ECG was measured using an automated ECG machine after at least 5 minutes of rest for the participant in a semi-recumbent or supine position. Number of participants with abnormal ECG findings at any time post-Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Primary
    End point timeframe
    Median of 6.143 weeks of drug exposure
    Notes
    [57] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis were performed.
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [58]
    3 [59]
    2 [60]
    5 [61]
    4 [62]
    14 [63]
    Units: Participants
        Abnormal-not clinically significant
    1
    3
    1
    4
    3
    4
        Abnormal-clinically significant
    0
    0
    0
    0
    0
    1
    Notes
    [58] - All Treated Population
    [59] - All Treated Population
    [60] - All Treated Population
    [61] - All Treated Population
    [62] - All Treated Population
    [63] - All Treated Population
    No statistical analyses for this end point

    Secondary: Maximum observed plasma concentration (Cmax) of GSK2849330-Part 1

    		 Close Top of page
    End point title
    		 Maximum observed plasma concentration (Cmax) of GSK2849330-Part 1
    End point description
    The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data is defined as Cmax. Blood samples were collected at indicated time points. The analysis was performed on pharmacokinetic (PK) parameter population which comprised of all participants from the PK concentration population (participants who received at least one dose of GSK2849330 and for whom at least one post-dose PK sample was obtained and analyzed) for whom valid and valuable PK parameters were derived. 99999 indicates data was not available. The geometric coefficient of variation could not be calculated as a single participant was analyzed at the specified time point.
    End point type
    Secondary
    End point timeframe
    Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [64]
    3 [65]
    2 [66]
    3 [67]
    3 [68]
    5 [69]
    Units: Nanograms per milliliter
    geometric mean (geometric coefficient of variation)
        Nanograms per milliliter
    29790.0 ( 99999 )
    62495.2 ( 34.8 )
    83845.0 ( 24.1 )
    233997.8 ( 2.7 )
    639127.3 ( 45.4 )
    778470.6 ( 14.5 )
    Notes
    [64] - PK Parameter Population
    [65] - PK Parameter Population
    [66] - PK Parameter Population
    [67] - PK Parameter Population
    [68] - PK Parameter Population
    [69] - PK Parameter Population
    No statistical analyses for this end point

    Secondary: Cmax of GSK2849330-Part 2

    		 Close Top of page
    End point title
    		 Cmax of GSK2849330-Part 2 [70]
    End point description
    PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.
    End point type
    Secondary
    End point timeframe
    Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose
    Notes
    [70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only GSK2849330 30 mg/kg weekly was analyzed in Part 2.
    End point values
    		 GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    0 [71]
    Units: Nanograms per milliliter
    geometric mean (geometric coefficient of variation)
        Nanograms per milliliter
    ( )
    Notes
    [71] - PK Parameter Population
    No statistical analyses for this end point

    Secondary: Time of occurrence of Cmax (Tmax) for GSK2849330-Part 1

    		 Close Top of page
    End point title
    		 Time of occurrence of Cmax (Tmax) for GSK2849330-Part 1
    End point description
    The time at which Cmax is observed was determined directly from the raw concentration-time data is defined as Tmax. Blood samples were collected at indicated time points for evaluation of pharmacokinetic parameters.
    End point type
    Secondary
    End point timeframe
    Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [72]
    3 [73]
    2 [74]
    3 [75]
    3 [76]
    5 [77]
    Units: Hours
    median (full range (min-max))
        Hours
    2.070 (2.070 to 2.070)
    2.130 (2.000 to 6.170)
    88.035 (6.370 to 169.700)
    2.280 (2.130 to 6.000)
    3.280 (2.300 to 6.230)
    2.100 (1.830 to 2.330)
    Notes
    [72] - PK Parameter Population
    [73] - PK Parameter Population
    [74] - PK Parameter Population
    [75] - PK Parameter Population
    [76] - PK Parameter Population
    [77] - PK Parameter Population
    No statistical analyses for this end point

    Secondary: Tmax for GSK2849330-Part 2

    		 Close Top of page
    End point title
    		 Tmax for GSK2849330-Part 2 [78]
    End point description
    PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.
    End point type
    Secondary
    End point timeframe
    Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose
    Notes
    [78] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only GSK2849330 30 mg/kg weekly was analyzed in Part 2.
    End point values
    		 GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    0 [79]
    Units: Hours
    median (full range (min-max))
        Hours
    ( to )
    Notes
    [79] - PK Parameter Population
    No statistical analyses for this end point

    Secondary: Area under the concentration time curve (AUC) to a fixed nominal time (AUC[0 to 168]) and AUC(0 to 336) for GSK2849330-Part 1

    		 Close Top of page
    End point title
    		 Area under the concentration time curve (AUC) to a fixed nominal time (AUC[0 to 168]) and AUC(0 to 336) for GSK2849330-Part 1
    End point description
    The AUC to a fixed nominal time AUC(0-168) and AUC(0-336) were calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Blood samples were collected at indicated time points for determination of PK parameters. 99999 indicates data is not available due to insufficient number of participants. Geometric coefficient of variation could not be calculated as a single participant was analyzed at the specified time point. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles).
    End point type
    Secondary
    End point timeframe
    Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [80]
    3 [81]
    2 [82]
    3 [83]
    3 [84]
    5 [85]
    Units: Hours*nanogram per milliliter
    geometric mean (geometric coefficient of variation)
        AUC(0 to 168); n=1, 3, 2, 3, 3, 5
    1962762.0 ( 99999 )
    5787797.8 ( 27.2 )
    618552.6 ( 20559.2 )
    18185733.6 ( 28.8 )
    54346531.5 ( 30.2 )
    54388333.7 ( 22.6 )
        AUC(0 to 336); 0, 3, 0, 3, 3, 0
    99999 ( 99999 )
    7855808.8 ( 28.7 )
    99999 ( 99999 )
    23409694.6 ( 39.4 )
    72404738.6 ( 34.2 )
    99999 ( 99999 )
    Notes
    [80] - PK Parameter Population
    [81] - PK Parameter Population
    [82] - PK Parameter Population
    [83] - PK Parameter Population
    [84] - PK Parameter Population
    [85] - PK Parameter Population
    No statistical analyses for this end point

    Secondary: AUC(0 to 168) and AUC(0 to 336) for GSK2849330-Part 2

    		 Close Top of page
    End point title
    		 AUC(0 to 168) and AUC(0 to 336) for GSK2849330-Part 2 [86]
    End point description
    PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.
    End point type
    Secondary
    End point timeframe
    Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose
    Notes
    [86] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Only GSK2849330 30 mg/kg weekly was analyzed in Part 2.
    End point values
    		 GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    0 [87]
    Units: Hours*nanogram per milliliter
    geometric mean (geometric coefficient of variation)
        Hours*nanogram per milliliter
    ( )
    Notes
    [87] - PK Parameter Population
    No statistical analyses for this end point

    Secondary: Serum HER3 from tumor tissue-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Serum HER3 from tumor tissue-Parts 1 and 2
    End point description
    Pre-treatment and on-treatment biopsy tissues (tumor and normal skin) were analyzed for markers of HER3 pathway such as HER3 that may indicate a pharmacodynamic (PD) response to GSK2849330. Serum HER3 (soluble HER3) analyses was performed. The analysis was performed on PD population which comprised of all participants who received at least one dose of GSK2849330 and for whom at least one evaluable paired pre-treatment PD sample and on-treatment PD sample were obtained and analyzed. Mean and standard deviation for serum HER3 is presented. 99999 indicates data was not available due to insufficient number of participants. Standard deviation could not be calculated as a single participant was analyzed at the specified time points. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Secondary
    End point timeframe
    Median of 6.143 weeks of drug exposure
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [88]
    3 [89]
    1 [90]
    5 [91]
    4 [92]
    12 [93]
    Units: Nanomoles
    arithmetic mean (standard deviation)
        Day 1; pre-dose; n=1, 3, 1, 5, 4, 12
    13.65 ( 99999 )
    17.11 ( 2.603 )
    16.66 ( 99999 )
    14.42 ( 4.004 )
    13.67 ( 4.681 )
    11.08 ( 5.322 )
        Day 1; 1 hour; n=1, 3, 1, 5, 4, 11
    11.12 ( 99999 )
    13.14 ( 2.966 )
    7.53 ( 99999 )
    10.76 ( 2.228 )
    9.55 ( 4.437 )
    5.59 ( 2.709 )
        Day 1; 6 hours; n=1, 3, 1, 5, 4, 10
    9.88 ( 99999 )
    13.71 ( 2.679 )
    12.99 ( 99999 )
    11.69 ( 4.058 )
    9.39 ( 4.586 )
    5.35 ( 2.031 )
        Day 2; n=0, 0, 1, 1, 1, 2
    99999 ( 99999 )
    99999 ( 99999 )
    8.12 ( 99999 )
    13.15 ( 99999 )
    4.59 ( 99999 )
    3.50 ( 2.001 )
        Day 8; n=1, 3, 1, 5, 4, 11
    10.14 ( 99999 )
    11.59 ( 4.353 )
    10.87 ( 99999 )
    10.85 ( 3.771 )
    6.32 ( 2.702 )
    6.05 ( 2.382 )
        Day 15; n=0, 2, 1, 3, 4, 10
    99999 ( 99999 )
    10.62 ( 1.110 )
    7.37 ( 99999 )
    11.38 ( 3.535 )
    9.84 ( 3.127 )
    4.66 ( 1.402 )
        Day 29; n=1, 3, 1, 4, 4, 8
    10.99 ( 99999 )
    12.18 ( 3.695 )
    7.69 ( 99999 )
    6.60 ( 3.220 )
    6.91 ( 4.621 )
    4.13 ( 1.815 )
        Follow-up; n=1, 2, 1, 3, 2, 5
    6.19 ( 99999 )
    9.22 ( 3.090 )
    14.86 ( 99999 )
    5.41 ( 1.406 )
    3.73 ( 0.424 )
    4.39 ( 2.975 )
    Notes
    [88] - PD Population
    [89] - PD Population
    [90] - PD Population
    [91] - PD Population
    [92] - PD Population
    [93] - PD Population
    No statistical analyses for this end point

    Secondary: Overall response rate (ORR)-Parts 1 and 2

    		 Close Top of page
    End point title
    		 Overall response rate (ORR)-Parts 1 and 2
    End point description
    ORR was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). ORR was calculated as the number of participants with best overall response of complete response (CR) and partial response (PR). CR=Disappearance of all target lesions. Any pathological lymph nodes must be <10 millimeter (mm) in the short axis and PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters (e.g., percent change from Baseline). An estimate to the true response rate for the number of participants analyzed is given. The 95% confidence interval was the exact confidence interval based on binomial proportion for ORR. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Secondary
    End point timeframe
    Median of 6.143 weeks of drug exposure
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [94]
    3 [95]
    2 [96]
    5 [97]
    4 [98]
    14 [99]
    Units: Participants
    number (confidence interval 95%)
        Participants
    0 (0.0 to 97.5)
    0 (0.0 to 70.8)
    0 (0.0 to 84.2)
    0 (0.0 to 52.2)
    0 (0.0 to 60.2)
    1 (0.2 to 33.9)
    Notes
    [94] - All Treated Population
    [95] - All Treated Population
    [96] - All Treated Population
    [97] - All Treated Population
    [98] - All Treated Population
    [99] - All Treated Population
    No statistical analyses for this end point

    Secondary: Number of participants with antibodies to GSK2849330 in serum

    		 Close Top of page
    End point title
    		 Number of participants with antibodies to GSK2849330 in serum
    End point description
    Serum samples were collected for the determination of anti-GSK2849330 antibodies using a validated immunoelectrochemiluminescent (ECL) assay. The assay involved screening, confirmation and titration steps (tiered-testing approach). If serum samples contained anti-GSK2849330 antibodies, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants who tested positive for anti-GSK2849330 antibody in confirmatory testing on Day 1 and at any time post-Baseline is presented. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Secondary
    End point timeframe
    Median of 6.143 weeks of drug exposure
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [100]
    3 [101]
    2 [102]
    5 [103]
    4 [104]
    14 [105]
    Units: Participants
        Day1; n=1, 3, 2, 5, 4, 13
    0
    0
    0
    0
    0
    1
        Any time post-Baseline; n=1, 3, 1, 5, 4, 7
    0
    0
    0
    0
    0
    0
    Notes
    [100] - All Treated Population
    [101] - All Treated Population
    [102] - All Treated Population
    [103] - All Treated Population
    [104] - All Treated Population
    [105] - All Treated Population
    No statistical analyses for this end point

    Secondary: Percentage of cluster of differentiation (CD) marker

    		 Close Top of page
    End point title
    		 Percentage of cluster of differentiation (CD) marker
    End point description
    Blood samples were collected on Day (D) 1 at pre-dose (pre) and at 1 hour (h) and 6 h post infusion for the analysis of markers to evaluate biological activity of GSK2849330. A pre-dose blood sample was collected on D8, D15 and D29 with additional blood sample collected at progression of disease. CDX241 represent CD45+CD3-CD56+CD16+CD69+CD107+, CDX243=CD45+CD3-CD56+CD16+CD69+CD107-; CDX244=CD45+CD3-CD56+CD16+CD69-CD107+ and CDX245=CD45+CD3-CD56+CD16+CD69-CD107-. For participants in GSK2849330 3 mg/kg weekly arm, two samples (S1 and S2) were collected for D15 analysis. 99999 indicates data was not available due to insufficient participants. Standard deviation could not be calculated as a single participant was analyzed at the specified time point. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    End point type
    Secondary
    End point timeframe
    Median of 6.143 weeks of drug exposure
    End point values
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Number of subjects analysed
    1 [106]
    3 [107]
    1 [108]
    5 [109]
    4 [110]
    12 [111]
    Units: Percentage of CD marker cells
    arithmetic mean (standard deviation)
        CD45+; D1; pre; n=1, 3, 1, 5, 4, 9
    99.80 ( 99999 )
    99.83 ( 0.058 )
    99.90 ( 99999 )
    99.76 ( 0.434 )
    99.93 ( 0.050 )
    101.57 ( 6.268 )
        CD45+; D1; 1 h; n=1, 3, 1, 5, 4, 9
    99.60 ( 99999 )
    99.87 ( 0.058 )
    99.80 ( 99999 )
    99.76 ( 0.434 )
    99.93 ( 0.050 )
    101.13 ( 4.656 )
        CD45+; D1; 6 h; n=1, 3, 1, 5, 4, 11
    99.80 ( 99999 )
    99.83 ( 0.058 )
    99.90 ( 99999 )
    99.8 ( 0.255 )
    99.93 ( 0.096 )
    101.02 ( 3.978 )
        CD45+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    99.10 ( 99999 )
    99.7 ( 0.424 )
    99999 ( 99999 )
    99.80 ( 99999 )
        CD45+; D8; n=1, 3, 0, 5, 4, 8
    100.00 ( 99999 )
    99.87 ( 0.058 )
    99999 ( 99999 )
    99.4 ( 1.231 )
    99.80 ( 0.400 )
    99.75 ( 0.576 )
        CD45+; D15;S1; n=1, 3, 1, 5, 4, 9
    99.80 ( 99999 )
    99.90 ( 0.000 )
    99.9 ( 99999 )
    99.78 ( 0.327 )
    99.78 ( 0.320 )
    100.33 ( 2.495 )
        CD45+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    99.8 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+; D29; n=1, 3, 1, 4, 4, 8
    99.90 ( 99999 )
    99.93 ( 0.058 )
    100.00 ( 99999 )
    99.78 ( 0.222 )
    99.75 ( 0.436 )
    100.80 ( 3.746 )
        CD45+; follow-up (FU); n=1, 2, 0, 3, 1, 4
    100.00 ( 99999 )
    99.85 ( 0.071 )
    99999 ( 99999 )
    99.63 ( 0.551 )
    99.30 ( 99999 )
    101.60 ( 4.827 )
        CD45+; unscheduled (USC); n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    100.00 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+; D1; pre;n=1, 3, 1, 5, 4, 9
    62.70 ( 99999 )
    69.00 ( 13.313 )
    58.80 ( 99999 )
    86.88 ( 2.580 )
    71.98 ( 10.832 )
    72.91 ( 8.027 )
        CD45+CD3+; D1; 1 h; n=1, 3, 1, 5, 4, 9
    76.20 ( 99999 )
    73.83 ( 9.646 )
    57.30 ( 99999 )
    87.08 ( 2.153 )
    75.80 ( 6.933 )
    74.36 ( 9.552 )
        CD45+CD3+; D1; 6 h; n=1, 3, 1, 5, 4, 11
    81.20 ( 99999 )
    72.43 ( 12.784 )
    62.70 ( 99999 )
    86.88 ( 2.580 )
    77.83 ( 5.065 )
    72.16 ( 10.282 )
        CD45+CD3+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    48.40 ( 99999 )
    86.60 ( 0.566 )
    99999 ( 99999 )
    77.00 ( 99999 )
        CD45+CD3+; D8; n=1, 3, 0, 5, 4, 8
    72.30 ( 99999 )
    69.67 ( 17.310 )
    99999 ( 99999 )
    86.30 ( 1.505 )
    77.53 ( 7.566 )
    75.31 ( 8.234 )
        CD45+CD3+; D15; S1; n=1, 3, 1, 5, 4, 9
    73.60 ( 99999 )
    68.97 ( 19.410 )
    36.8 ( 99999 )
    87.52 ( 1.359 )
    76.08 ( 8.844 )
    76.50 ( 5.723 )
        CD45+CD3+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    48.9 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+; D29; n=1, 3, 1, 4, 4, 8
    76.70 ( 99999 )
    69.97 ( 17.609 )
    36.20 ( 99999 )
    87.30 ( 1.753 )
    73.58 ( 9.783 )
    74.49 ( 12.798 )
        CD45+CD3+; FU; n=1, 2, 0, 3, 1, 4
    64.50 ( 99999 )
    77.15 ( 7.425 )
    99999 ( 99999 )
    83.53 ( 7.966 )
    42.50 ( 99999 )
    70.13 ( 11.425 )
        CD45+CD3+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    58.70 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+; D1; pre;n=1, 3, 1, 5, 4, 9
    9.60 ( 99999 )
    21.67 ( 6.929 )
    21.60 ( 99999 )
    35.14 ( 22.721 )
    24.95 ( 13.644 )
    25.39 ( 11.076 )
        CD45+CD3+CD8+; D1; 1 h; n=1, 3, 1, 5, 4, 9
    8.00 ( 99999 )
    20.20 ( 3.538 )
    20.50 ( 99999 )
    31.24 ( 21.617 )
    20.48 ( 10.935 )
    23.18 ( 10.434 )
        CD45+CD3+CD8+; D1; 6 h; n=1, 3, 1, 5, 4, 11
    8.20 ( 99999 )
    17.47 ( 2.548 )
    23.20 ( 99999 )
    30.82 ( 22.379 )
    23.38 ( 11.738 )
    22.86 ( 11.701 )
        CD45+CD3+CD8+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    21.20 ( 99999 )
    19.70 ( 7.071 )
    99999 ( 99999 )
    40.60 ( 99999 )
        CD45+CD3+CD8+; D8; n=1, 3, 0, 5, 4, 8
    10.50 ( 99999 )
    22.70 ( 4.987 )
    99999 ( 99999 )
    35.24 ( 22.320 )
    24.60 ( 12.511 )
    23.76 ( 9.382 )
        CD45+CD3+CD8+; D15; S1; n=1, 3, 1, 5, 4, 9
    9.70 ( 99999 )
    20.90 ( 6.843 )
    13 ( 99999 )
    36.46 ( 22.405 )
    26.25 ( 13.843 )
    27.00 ( 11.668 )
        CD45+CD3+CD8+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    15.7 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+; D29; n=1, 3, 1, 4, 4, 8
    11.10 ( 99999 )
    20.93 ( 6.110 )
    17.10 ( 99999 )
    40.85 ( 23.034 )
    23.05 ( 11.997 )
    20.40 ( 13.234 )
        CD45+CD3+CD8+; FU; n=1, 2, 0, 3, 1, 4
    7.90 ( 99999 )
    24.55 ( 4.455 )
    99999 ( 99999 )
    45.10 ( 29.487 )
    6.30 ( 99999 )
    31.88 ( 4.661 )
        CD45+CD3+CD8+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    21.00 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-; D1; pre n=1, 3, 1, 5, 4, 9
    50.90 ( 99999 )
    45.90 ( 9.124 )
    36.20 ( 99999 )
    50.76 ( 20.204 )
    45.58 ( 4.365 )
    47.71 ( 14.059 )
        CD45+CD3+CD8-; D1; 1 h; n=1, 3, 1, 5, 4, 9
    66.60 ( 99999 )
    52.77 ( 8.732 )
    36.50 ( 99999 )
    54.92 ( 19.213 )
    53.90 ( 6.349 )
    51.10 ( 17.633 )
        CD45+CD3+CD8-; D1; 6 h; n=1, 3, 1, 5, 4, 11
    72.00 ( 99999 )
    54.10 ( 13.421 )
    36.40 ( 99999 )
    55.26 ( 19.752 )
    53.28 ( 10.943 )
    49.26 ( 17.654 )
        CD45+CD3+CD8-; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    26.90 ( 99999 )
    66.35 ( 7.425 )
    99999 ( 99999 )
    36.60 ( 99999 )
        CD45+CD3+CD8-; D8; n=1, 3, 0, 5, 4, 8
    63.00 ( 99999 )
    46.80 ( 12.759 )
    99999 ( 99999 )
    50.48 ( 21.133 )
    51.70 ( 11.040 )
    51.48 ( 8.065 )
        CD45+CD3+CD8-; D15; S1; n=1, 3, 1, 5, 4, 9
    63.20 ( 99999 )
    48.37 ( 12.659 )
    24.3 ( 99999 )
    50.56 ( 21.357 )
    49.60 ( 9.910 )
    49.08 ( 13.029 )
        CD45+CD3+CD8-; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    36.1 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-; D29; n=1, 3, 1, 4, 4, 8
    65.40 ( 99999 )
    49.10 ( 12.137 )
    19.90 ( 99999 )
    45.55 ( 21.821 )
    50.43 ( 3.402 )
    54.63 ( 13.806 )
        CD45+CD3+CD8-; FU; n=1, 2, 0, 3, 1, 4
    56.40 ( 99999 )
    52.50 ( 3.394 )
    99999 ( 99999 )
    38.20 ( 21.565 )
    36.90 ( 99999 )
    37.53 ( 16.020 )
        CD45+CD3+CD8-; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    38.30 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+; D1; pre n=1, 3, 1, 5, 4, 9
    24.3 ( 99999 )
    14.50 ( 7.375 )
    25.20 ( 99999 )
    4.96 ( 1.757 )
    13.83 ( 12.467 )
    10.63 ( 8.253 )
        CD45+CD3-CD16+; D1; 1 h; n=1, 3, 1, 5, 4, 9
    9.40 ( 99999 )
    9.03 ( 5.972 )
    32.50 ( 99999 )
    4.44 ( 2.411 )
    8.00 ( 8.198 )
    8.90 ( 6.203 )
        CD45+CD3-CD16+; D1; 6 h; n=1, 3, 1, 5, 4, 11
    3.10 ( 99999 )
    5.80 ( 6.538 )
    23.80 ( 99999 )
    3.30 ( 2.314 )
    6.43 ( 4.407 )
    7.44 ( 4.569 )
        CD45+CD3-CD16+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    35.30 ( 99999 )
    2.50 ( 0.566 )
    99999 ( 99999 )
    4.10 ( 99999 )
        CD45+CD3-CD16+; D8; n=1, 3, 0, 5, 4, 8
    11.30 ( 99999 )
    14.71 ( 12.293 )
    99999 ( 99999 )
    5.62 ( 3.128 )
    9.23 ( 5.762 )
    11.23 ( 7.852 )
        CD45+CD3-CD16+; D15; S1; n=1, 3, 1, 5, 4, 9
    11.40 ( 99999 )
    13.73 ( 11.816 )
    47.7 ( 99999 )
    4.54 ( 3.138 )
    9.50 ( 6.470 )
    10.33 ( 7.555 )
        CD45+CD3-CD16+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    7.6 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+; D29; n=1, 3, 1, 4, 4, 8
    11.30 ( 99999 )
    11.83 ( 9.530 )
    37.10 ( 99999 )
    5.75 ( 2.654 )
    10.73 ( 9.999 )
    11.93 ( 7.323 )
        CD45+CD3-CD16+; FU; n=1, 2, 0, 3, 1, 4
    20.80 ( 99999 )
    6.65 ( 4.031 )
    99999 ( 99999 )
    6.67 ( 2.237 )
    43.50 ( 99999 )
    10.03 ( 10.920 )
        CD45+CD3-CD16+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    19.50 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+; D1; pre; n=1, 3, 1, 5, 4, 9
    25.70 ( 99999 )
    14.03 ( 5.636 )
    25.80 ( 99999 )
    5.88 ( 1.221 )
    15.93 ( 11.588 )
    12.16 ( 7.479 )
        CD45+CD3-CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9
    10.80 ( 99999 )
    10.13 ( 4.562 )
    32.80 ( 99999 )
    5.30 ( 1.581 )
    10.50 ( 7.470 )
    10.74 ( 6.300 )
        CD45+CD3-CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11
    4.20 ( 99999 )
    7.47 ( 5.934 )
    26.60 ( 99999 )
    4.70 ( 1.913 )
    9.43 ( 3.079 )
    10.71 ( 7.319 )
        CD45+CD3-CD56+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    42.40 ( 99999 )
    4.10 ( 0.141 )
    99999 ( 99999 )
    5.60 ( 99999 )
        CD45+CD3-CD56+; D8; n=1, 3, 0, 5, 4, 8
    13.70 ( 99999 )
    14.43 ( 10.625 )
    99999 ( 99999 )
    6.16 ( 2.574 )
    11.10 ( 4.808 )
    12.33 ( 7.733 )
        CD45+CD3-CD56+; D15; S1; n=1, 3, 1, 5, 4, 9
    13.50 ( 99999 )
    13.53 ( 11.288 )
    50.2 ( 99999 )
    5.96 ( 2.266 )
    11.73 ( 6.548 )
    8.39 ( 4.622 )
        CD45+CD3-CD56+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    8.7 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+; D29; n=1, 3, 1, 4, 4, 8
    13.10 ( 99999 )
    11.90 ( 8.502 )
    42.30 ( 99999 )
    6.18 ( 2.428 )
    13.73 ( 9.582 )
    12.48 ( 9.517 )
        CD45+CD3-CD56+; FU; n=1, 2, 0, 3, 1, 4
    22.00 ( 99999 )
    7.80 ( 1.556 )
    99999 ( 99999 )
    8.37 ( 3.493 )
    44.20 ( 99999 )
    11.95 ( 8.912 )
        CD45+CD3-CD56+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    22.10 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9
    3.30 ( 99999 )
    10.17 ( 8.905 )
    2.70 ( 99999 )
    13.18 ( 10.303 )
    6.20 ( 4.774 )
    4.67 ( 2.707 )
        CD45+CD3+CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9
    1.80 ( 99999 )
    8.03 ( 8.410 )
    1.70 ( 99999 )
    10.70 ( 7.601 )
    6.65 ( 7.102 )
    4.20 ( 3.321 )
        CD45+CD3+CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11
    1.10 ( 99999 )
    6.87 ( 7.566 )
    13.80 ( 99999 )
    12.50 ( 11.924 )
    8.50 ( 10.745 )
    4.17 ( 3.299 )
        CD45+CD3+CD56+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    3.50 ( 99999 )
    20.90 ( 14.001 )
    99999 ( 99999 )
    7.00 ( 99999 )
        CD45+CD3+CD56+; D8; n=1, 3, 0, 5, 4, 8
    3.40 ( 99999 )
    10.23 ( 8.977 )
    99999 ( 99999 )
    12.36 ( 8.813 )
    5.83 ( 2.756 )
    3.49 ( 2.801 )
        CD45+CD3+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9
    2.20 ( 99999 )
    8.40 ( 8.118 )
    1.30 ( 99999 )
    13.48 ( 12.640 )
    8.15 ( 3.746 )
    4.43 ( 3.015 )
        CD45+CD3+CD56+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    1.3 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+; D29; n=1, 3, 1, 4, 4, 8
    2.80 ( 99999 )
    9.33 ( 8.629 )
    3.80 ( 99999 )
    8.88 ( 5.197 )
    11.78 ( 9.751 )
    2.91 ( 2.635 )
        CD45+CD3+CD56+; FU; n=1, 2, 0, 3, 1, 4
    2.50 ( 99999 )
    16.20 ( 13.294 )
    99999 ( 99999 )
    16.07 ( 6.757 )
    3.50 ( 99999 )
    5.10 ( 2.665 )
        CD45+CD3+CD56+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    1.60 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9
    23.40 ( 99999 )
    12.23 ( 6.307 )
    23.30 ( 99999 )
    4.48 ( 1.638 )
    13.25 ( 12.307 )
    9.58 ( 7.480 )
        CD45+CD3-CD16+CD56+; D1;1 h; n=1, 3, 1, 5, 4, 9
    9.10 ( 99999 )
    8.10 ( 5.237 )
    31.10 ( 99999 )
    3.98 ( 2.244 )
    7.65 ( 8.118 )
    7.98 ( 5.768 )
        CD45+CD3-CD16+CD56+; D1;6 h; n=1,3,1,5,4,11
    3.00 ( 99999 )
    4.90 ( 5.403 )
    19.70 ( 99999 )
    2.92 ( 2.348 )
    6.10 ( 4.221 )
    6.22 ( 4.445 )
        CD45+CD3-CD16+CD56+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    33.60 ( 99999 )
    2.40 ( 0.566 )
    99999 ( 99999 )
    4.10 ( 99999 )
        CD45+CD3-CD16+CD56+; D8; n=1, 3, 0, 5, 4, 8
    10.80 ( 99999 )
    12.33 ( 10.979 )
    99999 ( 99999 )
    5.00 ( 2.891 )
    8.68 ( 5.465 )
    8.96 ( 6.217 )
        CD45+CD3-CD16+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9
    10.90 ( 99999 )
    11.93 ( 11.007 )
    43.5 ( 99999 )
    4.14 ( 2.926 )
    8.88 ( 6.357 )
    6.54 ( 4.360 )
        CD45+CD3-CD16+CD56+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    5.4 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD56+; D29; n=1, 3, 1, 4, 4, 8
    10.80 ( 99999 )
    10.20 ( 8.542 )
    32.90 ( 99999 )
    5.05 ( 2.357 )
    10.18 ( 9.932 )
    9.30 ( 6.776 )
        CD45+CD3-CD16+CD56+; FU; n=1, 2, 0, 3, 1, 4
    19.30 ( 99999 )
    5.50 ( 3.111 )
    99999 ( 99999 )
    6.07 ( 2.566 )
    41.90 ( 99999 )
    9.20 ( 9.937 )
        CD45+CD3-CD16+CD56+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    18.30 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD19+; D1; pre n=1, 3, 1, 5, 4, 9
    9.10 ( 99999 )
    12.67 ( 4.936 )
    12.30 ( 99999 )
    5.36 ( 3.364 )
    9.48 ( 4.769 )
    8.39 ( 3.194 )
        CD45+CD3-CD19+; D1;1 h; n=1, 3, 1, 5, 4, 9
    11.70 ( 99999 )
    13.77 ( 3.323 )
    8.30 ( 99999 )
    6.04 ( 3.492 )
    11.53 ( 6.211 )
    9.18 ( 3.819 )
        CD45+CD3-CD19+; D1;6 h; n=1,3,1,5,4,11
    11.30 ( 99999 )
    16.23 ( 3.329 )
    6.00 ( 99999 )
    6.36 ( 3.817 )
    10.83 ( 6.636 )
    9.00 ( 4.988 )
        CD45+CD3-CD19+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    6.40 ( 99999 )
    8.10 ( 0.141 )
    99999 ( 99999 )
    10.90 ( 99999 )
        CD45+CD3-CD19+; D8; n=1, 3, 0, 5, 4, 8
    10.70 ( 99999 )
    12.77 ( 4.701 )
    99999 ( 99999 )
    5.76 ( 3.895 )
    9.63 ( 4.786 )
    7.65 ( 4.176 )
        CD45+CD3-CD19+; D15; S1; n=1, 3, 1, 5, 4, 9
    10.60 ( 99999 )
    14.03 ( 6.116 )
    7.9 ( 99999 )
    5.10 ( 3.180 )
    9.25 ( 4.339 )
    8.90 ( 4.170 )
        CD45+CD3-CD19+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    26.2 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD19+; D29; n=1, 3, 1, 4, 4, 8
    8.90 ( 99999 )
    15.37 ( 7.392 )
    13.70 ( 99999 )
    5.10 ( 3.995 )
    10.53 ( 6.106 )
    7.44 ( 4.324 )
        CD45+CD3-CD19+; FU; n=1, 2, 0, 3, 1, 4
    10.00 ( 99999 )
    12.05 ( 4.313 )
    99999 ( 99999 )
    6.17 ( 8.361 )
    8.90 ( 99999 )
    8.33 ( 6.019 )
        CD45+CD3-CD19+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    15.90 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD14+; D1; pre; n=1, 3, 1, 5, 4, 9
    5.80 ( 99999 )
    4.87 ( 0.971 )
    10.40 ( 99999 )
    6.58 ( 1.293 )
    7.15 ( 2.029 )
    4.87 ( 1.406 )
        CD45+CD14+; D1;1 h; n=1, 3, 1, 5, 4, 9
    1.40 ( 99999 )
    3.63 ( 2.103 )
    11.30 ( 99999 )
    5.20 ( 1.461 )
    4.68 ( 2.926 )
    3.52 ( 1.713 )
        CD45+CD14+; D1;6 h; n=1,3,1,5,4,11
    4.50 ( 99999 )
    5.37 ( 2.804 )
    11.80 ( 99999 )
    6.24 ( 1.756 )
    5.80 ( 2.389 )
    5.23 ( 2.581 )
        CD45+CD14+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    5.30 ( 99999 )
    5.10 ( 2.828 )
    99999 ( 99999 )
    4.40 ( 99999 )
        CD45+CD14+; D8; n=1, 3, 0, 5, 4, 8
    7.30 ( 99999 )
    6.30 ( 0.872 )
    99999 ( 99999 )
    6.60 ( 1.594 )
    7.10 ( 2.223 )
    5.40 ( 2.115 )
        CD45+CD14+; D15; S1; n=1, 3, 1, 5, 4, 9
    4.70 ( 99999 )
    5.60 ( 1.652 )
    5.9 ( 99999 )
    6.66 ( 1.108 )
    6.93 ( 1.823 )
    5.47 ( 3.061 )
        CD45+CD14+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    18.9 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD14+; D29; n=1, 3, 1, 4, 4, 8
    5.00 ( 99999 )
    4.93 ( 0.231 )
    7.60 ( 99999 )
    5.53 ( 1.162 )
    6.68 ( 2.241 )
    4.61 ( 1.108 )
        CD45+CD14+; FU; n=1, 2, 0, 3, 1, 4
    7.50 ( 99999 )
    5.50 ( 1.273 )
    99999 ( 99999 )
    8.03 ( 0.862 )
    2.70 ( 99999 )
    4.98 ( 1.692 )
        CD45+CD14+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    8.50 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69+; D1; pre; n=1, 3, 1, 5, 4, 9
    67.92 ( 99999 )
    80.37 ( 3.710 )
    83.47 ( 99999 )
    80.92 ( 7.038 )
    82.50 ( 3.378 )
    75.71 ( 15.845 )
        CD45+CD3-CD16+CD69+; D1;1 h; n=1, 3, 1, 5, 4, 9
    76.94 ( 99999 )
    79.76 ( 2.213 )
    87.72 ( 99999 )
    81.88 ( 8.557 )
    86.01 ( 3.898 )
    78.53 ( 16.993 )
        CD45+CD3-CD16+CD69+; D1;6 h; n=1,3,1,5,4,11
    77.72 ( 99999 )
    76.99 ( 12.536 )
    90.79 ( 99999 )
    84.25 ( 5.802 )
    84.57 ( 4.448 )
    79.79 ( 12.178 )
        CD45+CD3-CD16+CD69+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    91.00 ( 99999 )
    89.03 ( 3.776 )
    99999 ( 99999 )
    88.05 ( 99999 )
        CD45+CD3-CD16+CD69+; D8; n=1, 3, 0, 5, 4, 8
    77.29 ( 99999 )
    75.83 ( 5.870 )
    99999 ( 99999 )
    81.34 ( 10.373 )
    79.91 ( 2.014 )
    70.93 ( 21.532 )
        CD45+CD3-CD16+CD69+; D15;S1; n=1, 3, 1, 5, 4, 9
    81.61 ( 99999 )
    79.04 ( 3.286 )
    96.49 ( 99999 )
    80.28 ( 6.867 )
    81.68 ( 7.216 )
    78.53 ( 20.178 )
        CD45+CD3-CD16+CD69+; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    92.76 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69+; D29; n=1, 3, 1, 4, 4, 8
    79.28 ( 99999 )
    81.92 ( 2.273 )
    85.01 ( 99999 )
    80.73 ( 6.688 )
    83.00 ( 6.240 )
    74.56 ( 17.788 )
        CD45+CD3-CD16+CD69+; FU; n=1, 2, 0, 3, 1, 4
    77.38 ( 99999 )
    84.40 ( 1.506 )
    99999 ( 99999 )
    81.52 ( 12.737 )
    76.46 ( 99999 )
    80.85 ( 19.555 )
        CD45+CD3-CD16+CD69+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    64.88 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD107+; D1; pre; n=1, 3, 1, 5, 4, 9
    7.06 ( 99999 )
    13.40 ( 5.851 )
    18.18 ( 99999 )
    19.27 ( 13.221 )
    23.96 ( 12.309 )
    25.04 ( 30.481 )
        CD45+CD3-CD16+CD107+; D1;1 h; n=1, 3, 1, 5,4,9
    12.19 ( 99999 )
    15.18 ( 8.160 )
    8.77 ( 99999 )
    21.43 ( 13.416 )
    24.66 ( 13.827 )
    23.16 ( 24.866 )
        CD45+CD3-CD16+CD107+; D1;6 h; n=1,3,1,5,4,11
    14.85 ( 99999 )
    15.30 ( 6.477 )
    40.79 ( 99999 )
    32.01 ( 16.156 )
    21.55 ( 12.001 )
    21.82 ( 17.204 )
        CD45+CD3-CD16+CD107+; D2; n=0, 0, 1, 2, 0, 1
    99999 ( 99999 )
    99999 ( 99999 )
    26.00 ( 99999 )
    31.96 ( 9.454 )
    99999 ( 99999 )
    30.82 ( 99999 )
        CD45+CD3-CD16+CD107+; D8; n=1, 3, 0, 5, 4, 8
    33.73 ( 99999 )
    6.90 ( 3.044 )
    99999 ( 99999 )
    22.42 ( 10.572 )
    14.43 ( 1.615 )
    27.85 ( 27.884 )
        CD45+CD3-CD16+CD107+; D15; S1; n=1, 3, 1, 5, 4, 9
    17.29 ( 99999 )
    7.72 ( 4.937 )
    38.6 ( 99999 )
    17.00 ( 8.663 )
    18.30 ( 3.558 )
    21.68 ( 15.816 )
        CD45+CD3-CD16+CD107+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    65.89 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD107+; D29; n=1, 3, 1, 4, 4, 8
    16.94 ( 99999 )
    8.78 ( 3.719 )
    52.86 ( 99999 )
    19.08 ( 4.869 )
    27.70 ( 12.686 )
    17.22 ( 6.799 )
        CD45+CD3-CD16+CD107+; FU; n=1, 2, 0, 3, 1, 4
    14.38 ( 99999 )
    22.49 ( 13.902 )
    99999 ( 99999 )
    31.28 ( 29.410 )
    11.64 ( 99999 )
    27.42 ( 15.633 )
        CD45+CD3-CD16+CD107+; USC; n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    16.51 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69+CD107+; D1; pre; n=1,3,1,5,4,9
    6.86 ( 99999 )
    13.33 ( 5.869 )
    18.18 ( 99999 )
    19.05 ( 12.990 )
    23.53 ( 11.967 )
    24.68 ( 30.659 )
        CD45+CD3-CD16+CD69+CD107+; D1;1 h;n=1,3,1,5,4,9
    11.81 ( 99999 )
    14.86 ( 7.795 )
    8.77 ( 99999 )
    21.29 ( 13.208 )
    24.42 ( 13.709 )
    22.85 ( 24.965 )
        CD45+CD3-CD16+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
    14.85 ( 99999 )
    15.29 ( 6.364 )
    38.16 ( 99999 )
    31.96 ( 16.199 )
    21.33 ( 11.655 )
    21.34 ( 17.411 )
        CD45+CD3-CD16+CD69+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    26.00 ( 99999 )
    31.42 ( 10.218 )
    99999 ( 99999 )
    30.19 ( 99999 )
        CD45+CD3-CD16+CD69+CD107+; D8; n=1,3,0,5,4,8
    32.80 ( 99999 )
    6.77 ( 3.013 )
    99999 ( 99999 )
    22.35 ( 10.534 )
    14.40 ( 1.591 )
    27.19 ( 27.949 )
        CD45+CD3-CD16+CD69+CD107+; D15; S1;n=1,3,1,5,4,9
    16.92 ( 99999 )
    7.60 ( 4.890 )
    38.6 ( 99999 )
    16.94 ( 8.669 )
    18.11 ( 3.584 )
    21.11 ( 16.206 )
        CD45+CD3-CD16+CD69+CD107+; D15; S2;n=0,0,1,0,0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    64.8 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69+CD107+; D29; n=1,3,1,4,4,8
    16.42 ( 99999 )
    8.70 ( 3.598 )
    50.41 ( 99999 )
    18.76 ( 4.922 )
    27.36 ( 12.492 )
    16.08 ( 6.127 )
        CD45+CD3-CD16+CD69+CD107+; FU; n=1,2,0,3,1,4
    14.34 ( 99999 )
    22.24 ( 13.548 )
    99999 ( 99999 )
    31.06 ( 29.550 )
    11.56 ( 99999 )
    27.16 ( 15.866 )
        CD45+CD3-CD16+CD69+CD107+; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    15.77 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69+CD107-; D1;pre; n=1,3,1,5,4,9
    61.07 ( 99999 )
    67.04 ( 7.996 )
    65.29 ( 99999 )
    61.87 ( 9.438 )
    58.97 ( 12.115 )
    51.03 ( 22.210 )
        CD45+CD3-CD16+CD69+CD107-; D1;1 h;n=1,3,1,5,4,9
    65.12 ( 99999 )
    64.90 ( 8.250 )
    78.95 ( 99999 )
    60.59 ( 8.489 )
    61.59 ( 10.979 )
    55.68 ( 18.837 )
        CD45+CD3-CD16+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
    62.87 ( 99999 )
    61.71 ( 10.282 )
    52.63 ( 99999 )
    52.29 ( 11.006 )
    63.25 ( 9.771 )
    58.44 ( 14.956 )
        CD45+CD3-CD16+CD69+CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    65.00 ( 99999 )
    57.62 ( 13.987 )
    99999 ( 99999 )
    57.86 ( 99999 )
        CD45+CD3-CD16+CD69+CD107-; D8; n=1,3,0,5,4,8
    44.49 ( 99999 )
    69.06 ( 8.555 )
    99999 ( 99999 )
    58.99 ( 8.379 )
    65.52 ( 2.097 )
    43.74 ( 17.564 )
        CD45+CD3-CD16+CD69+CD107-; D15;S1; n=1,3,1,5,4,9
    64.68 ( 99999 )
    71.45 ( 1.611 )
    57.89 ( 99999 )
    63.34 ( 4.338 )
    63.57 ( 6.498 )
    57.42 ( 15.273 )
        CD45+CD3-CD16+CD69+CD107-; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    27.96 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69+CD107-; D29; n=1,3,1,4,4,8
    62.87 ( 99999 )
    73.22 ( 4.103 )
    34.60 ( 99999 )
    61.98 ( 6.511 )
    55.64 ( 6.702 )
    58.48 ( 19.691 )
        CD45+CD3-CD16+CD69+CD107-; FU; n=1,2,0,3,1,4
    63.04 ( 99999 )
    62.16 ( 15.047 )
    99999 ( 99999 )
    50.46 ( 18.585 )
    64.90 ( 99999 )
    53.69 ( 9.671 )
        CD45+CD3-CD16+CD69+CD107-; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    49.11 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69-CD107+; D1;pre n=1,3,1,5,4,9
    0.21 ( 99999 )
    0.07 ( 0.115 )
    0.00 ( 99999 )
    0.22 ( 0.265 )
    0.43 ( 0.395 )
    0.36 ( 0.740 )
        CD45+CD3-CD16+CD69-CD107+; D1;1 h;n=1,3,1,5,4,9
    0.38 ( 99999 )
    0.31 ( 0.399 )
    0.00 ( 99999 )
    0.14 ( 0.238 )
    0.24 ( 0.441 )
    0.32 ( 0.494 )
        CD45+CD3-CD16+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
    0.00 ( 99999 )
    0.09 ( 0.162 )
    2.63 ( 99999 )
    0.05 ( 0.069 )
    0.23 ( 0.403 )
    0.48 ( 1.014 )
        CD45+CD3-CD16+CD69-CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    0.00 ( 99999 )
    0.54 ( 0.764 )
    99999 ( 99999 )
    0.63 ( 99999 )
        CD45+CD3-CD16+CD69-CD107+; D8; n=1,3,0,5,4,8
    0.94 ( 99999 )
    0.14 ( 0.029 )
    99999 ( 99999 )
    0.07 ( 0.100 )
    0.04 ( 0.041 )
    0.66 ( 0.524 )
        CD45+CD3-CD16+CD69-CD107+; D15;S1; n=1,3,1,5,4,9
    0.37 ( 99999 )
    0.12 ( 0.102 )
    0.00 ( 99999 )
    0.05 ( 0.121 )
    0.19 ( 0.236 )
    0.56 ( 0.890 )
        CD45+CD3-CD16+CD69-CD107+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    1.09 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69-CD107+; D29; n=1,3,1,4,4,8
    0.52 ( 99999 )
    0.07 ( 0.127 )
    2.45 ( 99999 )
    0.32 ( 0.326 )
    0.34 ( 0.241 )
    1.14 ( 1.844 )
        CD45+CD3-CD16+CD69-CD107+; FU; n=1,2,0,3,1,4
    0.03 ( 99999 )
    0.26 ( 0.361 )
    99999 ( 99999 )
    0.22 ( 0.333 )
    0.09 ( 99999 )
    0.27 ( 0.324 )
        CD45+CD3-CD16+CD69-CD107+; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    0.74 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69-CD107-; D1;pre; n=1,3,1,5,4,9
    31.87 ( 99999 )
    19.57 ( 3.611 )
    16.53 ( 99999 )
    18.86 ( 7.256 )
    17.07 ( 3.528 )
    23.98 ( 15.442 )
        CD45+CD3-CD16+CD69-CD107-; D1;1 h;n=1,3,1,5,4,9
    22.68 ( 99999 )
    19.93 ( 2.396 )
    12.28 ( 99999 )
    17.98 ( 8.736 )
    13.75 ( 3.880 )
    21.36 ( 16.671 )
        CD45+CD3-CD16+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
    22.28 ( 99999 )
    22.91 ( 12.511 )
    6.58 ( 99999 )
    15.70 ( 5.783 )
    15.21 ( 4.603 )
    19.98 ( 11.842 )
        CD45+CD3-CD16+CD69-CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    9.00 ( 99999 )
    10.43 ( 4.540 )
    99999 ( 99999 )
    11.32 ( 99999 )
        CD45+CD3-CD16+CD69-CD107-; D8; n=1,3,0,5,4,8
    21.78 ( 99999 )
    24.03 ( 5.842 )
    99999 ( 99999 )
    18.63 ( 10.331 )
    20.05 ( 2.014 )
    28.47 ( 21.443 )
        CD45+CD3-CD16+CD69-CD107-; D15; S1;n=1,3,1,5,4,9
    18.03 ( 99999 )
    20.84 ( 3.338 )
    3.51 ( 99999 )
    19.67 ( 6.810 )
    18.13 ( 7.060 )
    20.92 ( 19.349 )
        CD45+CD3-CD16+CD69-CD107-; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    6.15 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD16+CD69-CD107-; D29; n=1,3,1,4,4,8
    20.20 ( 99999 )
    18.00 ( 2.247 )
    12.53 ( 99999 )
    18.97 ( 6.747 )
    16.67 ( 6.466 )
    24.35 ( 16.239 )
        CD45+CD3-CD16+CD69-CD107-; FU; n=1,2,0,3,1,4
    22.59 ( 99999 )
    15.35 ( 1.146 )
    99999 ( 99999 )
    18.34 ( 12.586 )
    23.54 ( 99999 )
    18.89 ( 19.247 )
        CD45+CD3-CD16+CD69-CD107-; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    34.38 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69+; D1;pre; n=1,3,1,5,4,9
    67.22 ( 99999 )
    78.33 ( 3.952 )
    82.26 ( 99999 )
    77.55 ( 7.943 )
    77.94 ( 6.341 )
    71.81 ( 14.980 )
        CD45+CD3-CD56+CD69+; D1;1 h;n=1,3,1,5,4,9
    75.33 ( 99999 )
    77.13 ( 4.906 )
    86.96 ( 99999 )
    79.21 ( 8.936 )
    80.38 ( 5.074 )
    73.55 ( 18.249 )
        CD45+CD3-CD56+CD69+;D1;6 h;n=1,3,1,5,4,11
    79.56 ( 99999 )
    74.82 ( 11.935 )
    92.92 ( 99999 )
    80.05 ( 5.668 )
    79.33 ( 8.307 )
    74.28 ( 14.068 )
        CD45+CD3-CD56+CD69+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    87.50 ( 99999 )
    84.69 ( 5.862 )
    99999 ( 99999 )
    84.79 ( 99999 )
        CD45+CD3-CD56+CD69+; D8; n=1,3,0,5,4,8
    75.33 ( 99999 )
    72.08 ( 3.948 )
    99999 ( 99999 )
    77.49 ( 9.757 )
    75.71 ( 6.039 )
    64.20 ( 17.380 )
        CD45+CD3-CD56+CD69+; D15;S1; n=1,3,1,5,4,9
    80.07 ( 99999 )
    76.83 ( 2.746 )
    93.33 ( 99999 )
    76.69 ( 5.772 )
    77.05 ( 1.250 )
    74.14 ( 18.976 )
        CD45+CD3-CD56+CD69+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    90.79 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69+; D29; n=1,3,1,4,4,8
    76.99 ( 99999 )
    80.41 ( 3.445 )
    83.53 ( 99999 )
    77.90 ( 5.693 )
    78.39 ( 3.376 )
    72.21 ( 20.172 )
        CD45+CD3-CD56+CD69+; FU; n=1,2,0,3,1,4
    75.72 ( 99999 )
    83.15 ( 0.643 )
    99999 ( 99999 )
    78.85 ( 8.804 )
    76.62 ( 99999 )
    75.78 ( 15.172 )
        CD45+CD3-CD56+CD69+; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    64.59 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD107+; D1; pre; n=1,3,1,5,4,9
    2.47 ( 99999 )
    11.70 ( 5.812 )
    15.32 ( 99999 )
    16.30 ( 12.987 )
    20.36 ( 10.285 )
    15.35 ( 12.755 )
        CD45+CD3-CD56+CD107+; D1;1 h;n=1,3,1,5,4,9
    5.13 ( 99999 )
    13.87 ( 7.853 )
    6.69 ( 99999 )
    17.11 ( 11.990 )
    18.36 ( 8.295 )
    13.92 ( 14.620 )
        CD45+CD3-CD56+CD107+;D1;6 h;n=1,3,1,5,4,11
    14.60 ( 99999 )
    16.66 ( 7.368 )
    31.76 ( 99999 )
    23.41 ( 13.644 )
    19.50 ( 10.930 )
    17.82 ( 13.218 )
        CD45+CD3-CD56+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    21.67 ( 99999 )
    28.04 ( 7.347 )
    99999 ( 99999 )
    26.27 ( 99999 )
        CD45+CD3-CD56+CD107+; D8; n=1,3,0,5,4,8
    32.45 ( 99999 )
    6.79 ( 2.953 )
    99999 ( 99999 )
    17.46 ( 7.730 )
    12.81 ( 2.027 )
    15.17 ( 12.783 )
        CD45+CD3-CD56+CD107+; D15;S1; n=1,3,1,5,4,9
    15.54 ( 99999 )
    6.48 ( 3.558 )
    39.17 ( 99999 )
    14.18 ( 7.919 )
    13.95 ( 4.221 )
    16.02 ( 10.352 )
        CD45+CD3-CD56+CD107+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    54.4 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD107+; D29; n=1,3,1,4,4,8
    15.85 ( 99999 )
    7.77 ( 3.841 )
    48.21 ( 99999 )
    15.09 ( 1.735 )
    22.89 ( 7.527 )
    17.13 ( 5.406 )
        CD45+CD3-CD56+CD107+; FU; n=1,2,0,3,1,4
    13.08 ( 99999 )
    19.93 ( 11.469 )
    99999 ( 99999 )
    26.54 ( 22.053 )
    11.46 ( 99999 )
    23.63 ( 17.232 )
        CD45+CD3-CD56+CD107+; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    16.45 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69+CD107+; D1; pre n=1,3,1,5,4,9
    2.45 ( 99999 )
    11.58 ( 5.907 )
    15.32 ( 99999 )
    15.98 ( 12.746 )
    19.90 ( 9.878 )
    15.06 ( 12.804 )
        CD45+CD3-CD56+CD69+CD107+; D1;1 h;n=1,3,1,5,4,9
    4.97 ( 99999 )
    13.56 ( 7.455 )
    6.96 ( 99999 )
    16.90 ( 11.974 )
    17.72 ( 8.423 )
    13.60 ( 14.641 )
        CD45+CD3-CD56+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
    14.60 ( 99999 )
    15.94 ( 6.586 )
    31.76 ( 99999 )
    23.27 ( 13.781 )
    19.15 ( 10.796 )
    15.67 ( 9.351 )
        CD45+CD3-CD56+CD69+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    21.67 ( 99999 )
    27.36 ( 7.460 )
    99999 ( 99999 )
    25.81 ( 99999 )
        CD45+CD3-CD56+CD69+CD107+; D8; n=1,3,0,5,4,8
    31.18 ( 99999 )
    6.63 ( 2.770 )
    99999 ( 99999 )
    17.32 ( 7.645 )
    12.69 ( 2.047 )
    14.33 ( 12.481 )
        CD45+CD3-CD56+CD69+CD107+; D15;S1; n=1,3,1,5,4,9
    15.13 ( 99999 )
    6.40 ( 3.545 )
    39.17 ( 99999 )
    14.03 ( 7.922 )
    13.80 ( 4.123 )
    15.58 ( 10.540 )
        CD45+CD3-CD56+CD69+CD107+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    54.27 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69+CD107+; D29; n=1,3,1,4,4,8
    15.34 ( 99999 )
    7.77 ( 3.841 )
    46.54 ( 99999 )
    14.70 ( 1.922 )
    22.55 ( 7.441 )
    15.59 ( 4.963 )
        CD45+CD3-CD56+CD69+CD107+; FU; n=1,2,0,3,1,4
    13.01 ( 99999 )
    19.60 ( 11.130 )
    99999 ( 99999 )
    26.27 ( 22.189 )
    11.38 ( 99999 )
    23.00 ( 16.629 )
        CD45+CD3-CD56+CD69+CD107+; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    15.52 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69+CD107-; D1; pre; n=1,3,1,5,4,9
    64.78 ( 99999 )
    66.74 ( 7.360 )
    66.94 ( 99999 )
    61.56 ( 9.286 )
    58.04 ( 12.938 )
    56.75 ( 10.180 )
        CD45+CD3-CD56+CD69+CD107-; D1;1 h;n=1,3,1,5,4,9
    70.36 ( 99999 )
    63.58 ( 7.453 )
    80.00 ( 99999 )
    62.31 ( 7.582 )
    62.66 ( 8.744 )
    59.95 ( 15.044 )
        CD45+CD3-CD56+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
    64.96 ( 99999 )
    58.88 ( 10.865 )
    61.18 ( 99999 )
    56.78 ( 8.650 )
    60.18 ( 9.203 )
    58.62 ( 14.204 )
        CD45+CD3-CD56+CD69+CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    65.83 ( 99999 )
    57.33 ( 13.329 )
    99999 ( 99999 )
    58.99 ( 99999 )
        CD45+CD3-CD56+CD69+CD107-; D15;S1; n=1,3,1,5,4,9
    64.95 ( 99999 )
    70.43 ( 0.830 )
    54.17 ( 99999 )
    62.66 ( 4.313 )
    63.25 ( 5.044 )
    58.55 ( 14.595 )
        CD45+CD3-CD56+CD69+CD107-; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    36.52 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69+CD107-; D8; n=1,3,0,5,4,8
    44.15 ( 99999 )
    65.44 ( 6.176 )
    99999 ( 99999 )
    60.18 ( 8.140 )
    63.02 ( 5.005 )
    49.87 ( 13.422 )
        CD45+CD3-CD56+CD69+CD107-; D29; n=1,3,1,4,4,8
    61.65 ( 99999 )
    72.64 ( 2.420 )
    36.99 ( 99999 )
    63.21 ( 4.900 )
    55.84 ( 6.851 )
    56.62 ( 21.533 )
        CD45+CD3-CD56+CD69+CD107-; FU; n=1,2,0,3,1,4
    62.71 ( 99999 )
    63.55 ( 11.780 )
    99999 ( 99999 )
    52.58 ( 16.165 )
    65.24 ( 99999 )
    52.78 ( 12.864 )
        CD45+CD3-CD56+CD69+CD107-; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    49.07 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69-CD107+; D1; pre; n=1,3,1,5,4,9
    0.03 ( 99999 )
    0.11 ( 0.095 )
    0.00 ( 99999 )
    0.31 ( 0.267 )
    0.46 ( 0.425 )
    0.29 ( 0.558 )
        CD45+CD3-CD56+CD69-CD107+; D1;1 h;n=1,3,1,5,4,9
    0.17 ( 99999 )
    0.31 ( 0.412 )
    0.00 ( 99999 )
    0.21 ( 0.123 )
    0.64 ( 0.660 )
    0.32 ( 0.364 )
        CD45+CD3-CD56+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
    0.00 ( 99999 )
    0.72 ( 0.968 )
    0.00 ( 99999 )
    0.14 ( 0.226 )
    0.35 ( 0.262 )
    2.15 ( 5.749 )
        CD45+CD3-CD56+CD69-CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    0.00 ( 99999 )
    0.68 ( 0.113 )
    99999 ( 99999 )
    0.46 ( 99999 )
        CD45+CD3-CD56+CD69-CD107+; D8; n=1,3,0,5,4,8
    1.27 ( 99999 )
    0.16 ( 0.182 )
    99999 ( 99999 )
    0.14 ( 0.186 )
    0.11 ( 0.109 )
    0.84 ( 1.031 )
        CD45+CD3-CD56+CD69-CD107+; D15;S1; n=1,3,1,5,4,9
    0.41 ( 99999 )
    0.09 ( 0.076 )
    0 ( 99999 )
    0.15 ( 0.145 )
    0.15 ( 0.174 )
    0.44 ( 0.638 )
        CD45+CD3-CD56+CD69-CD107+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    0.14 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69-CD107+; D29; n=1,3,1,4,4,8
    0.50 ( 99999 )
    0.00 ( 0.000 )
    1.67 ( 99999 )
    0.39 ( 0.541 )
    0.35 ( 0.145 )
    1.54 ( 2.079 )
        CD45+CD3-CD56+CD69-CD107+; FU; n=1,2,0,3,1,4
    0.07 ( 99999 )
    0.34 ( 0.332 )
    99999 ( 99999 )
    0.27 ( 0.379 )
    0.08 ( 99999 )
    0.62 ( 0.678 )
        CD45+CD3-CD56+CD69-CD107+; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    0.93 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69-CD107-; D1; pre; n=1,3,1,5,4,9
    32.75 ( 99999 )
    21.56 ( 3.938 )
    17.74 ( 99999 )
    22.14 ( 8.116 )
    21.60 ( 6.379 )
    27.91 ( 14.759 )
        CD45+CD3-CD56+CD69-CD107-; D1;1 h;n=1,3,1,5,4,9
    24.50 ( 99999 )
    22.55 ( 5.154 )
    13.04 ( 99999 )
    20.58 ( 8.921 )
    18.99 ( 4.842 )
    26.13 ( 18.140 )
        CD45+CD3-CD56+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
    20.44 ( 99999 )
    24.46 ( 11.748 )
    7.06 ( 99999 )
    19.81 ( 5.486 )
    20.36 ( 8.302 )
    23.56 ( 13.128 )
        CD45+CD3-CD56+CD69-CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    12.50 ( 99999 )
    14.64 ( 5.975 )
    99999 ( 99999 )
    14.75 ( 99999 )
        CD45+CD3-CD56+CD69-CD107-; D8; n=1,3,0,5,4,8
    23.40 ( 99999 )
    27.76 ( 3.835 )
    99999 ( 99999 )
    22.37 ( 9.797 )
    24.18 ( 5.949 )
    34.96 ( 16.868 )
        CD45+CD3-CD56+CD69-CD107-; D15;S1; n=1,3,1,5,4,9
    19.57 ( 99999 )
    23.09 ( 2.774 )
    6.67 ( 99999 )
    23.16 ( 5.735 )
    22.81 ( 1.095 )
    25.43 ( 18.427 )
        CD45+CD3-CD56+CD69-CD107-; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    9.08 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD69-CD107-; D29; n=1,3,1,4,4,8
    22.56 ( 99999 )
    19.59 ( 3.445 )
    14.80 ( 99999 )
    21.73 ( 5.751 )
    21.27 ( 3.470 )
    26.26 ( 18.208 )
        CD45+CD3-CD56+CD69-CD107-; FU; n=1,2,0,3,1,4
    24.28 ( 99999 )
    16.52 ( 0.311 )
    99999 ( 99999 )
    20.87 ( 8.475 )
    23.30 ( 99999 )
    23.60 ( 15.370 )
        CD45+CD3-CD56+CD69-CD107-; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    34.48 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD16+CD69+; D1; pre; n=1,3,1,5,4,9
    67.96 ( 99999 )
    79.63 ( 3.253 )
    83.93 ( 99999 )
    80.66 ( 7.578 )
    82.35 ( 3.605 )
    75.53 ( 16.495 )
        CD45+CD3-CD56+CD16+CD69+; D1;1 h;n=1,3,1,5,4,9
    76.86 ( 99999 )
    79.33 ( 2.688 )
    88.07 ( 99999 )
    81.64 ( 9.116 )
    85.57 ( 3.640 )
    77.45 ( 18.036 )
        CD45+CD3-CD56+CD16+CD69+;D1;6 h;n=1,3,1,5,4,11
    78.24 ( 99999 )
    76.67 ( 11.942 )
    93.65 ( 99999 )
    83.35 ( 5.763 )
    83.95 ( 4.687 )
    78.92 ( 13.044 )
        CD45+CD3-CD56+CD16+CD69+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    90.53 ( 99999 )
    89.13 ( 3.147 )
    99999 ( 99999 )
    87.90 ( 99999 )
        CD45+CD3-CD56+CD16+CD69+; D8; n=1,3,0,5,4,8
    77.01 ( 99999 )
    75.37 ( 5.656 )
    99999 ( 99999 )
    80.55 ( 10.272 )
    79.75 ( 2.003 )
    70.62 ( 21.607 )
        CD45+CD3-CD56+CD16+CD69+; D15;S1; n=1,3,1,5,4,9
    81.53 ( 99999 )
    78.47 ( 3.127 )
    97.12 ( 99999 )
    79.94 ( 6.952 )
    80.67 ( 5.845 )
    79.09 ( 19.651 )
        CD45+CD3-CD56+CD16+CD69+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    94.42 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD16+CD69+; D29; n=1,3,1,4,4,8
    78.98 ( 99999 )
    81.90 ( 2.566 )
    85.89 ( 99999 )
    80.16 ( 7.448 )
    82.36 ( 4.976 )
    74.62 ( 18.799 )
        CD45+CD3-CD56+CD16+CD69+; FU; n=1,2,0,3,1,4
    77.43 ( 99999 )
    83.80 ( 1.485 )
    99999 ( 99999 )
    81.09 ( 12.356 )
    76.73 ( 99999 )
    80.93 ( 19.159 )
        CD45+CD3-CD56+CD16+CD69+; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    65.35 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD16+CD107+; D1;pre; n=1,3,1,5,4,9
    6.82 ( 99999 )
    12.17 ( 5.660 )
    16.96 ( 99999 )
    17.55 ( 13.586 )
    22.71 ( 12.190 )
    23.18 ( 31.567 )
        CD45+CD3-CD56+CD16+CD107+; D1;1 h;n=1,3,1,5,4,9
    12.40 ( 99999 )
    14.37 ( 7.788 )
    7.34 ( 99999 )
    19.24 ( 13.929 )
    23.33 ( 14.182 )
    20.40 ( 26.478 )
        CD45+CD3-CD56+CD16+CD107+;D1;6 h;n=1,3,1,5,4,11
    15.03 ( 99999 )
    14.86 ( 7.082 )
    31.75 ( 99999 )
    27.52 ( 16.167 )
    20.47 ( 12.384 )
    19.35 ( 17.934 )
        CD45+CD3-CD56+CD16+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    25.26 ( 99999 )
    32.24 ( 9.970 )
    99999 ( 99999 )
    30.57 ( 99999 )
        CD45+CD3-CD56+CD16+CD107+; D8; n=1,3,0,5,4,8
    33.08 ( 99999 )
    6.53 ( 3.339 )
    99999 ( 99999 )
    18.59 ( 9.084 )
    13.90 ( 2.089 )
    26.69 ( 33.377 )
        CD45+CD3-CD56+CD16+CD107+; D15;S1; n=1,3,1,5,4,9
    16.23 ( 99999 )
    6.20 ( 4.025 )
    40.38 ( 99999 )
    14.69 ( 8.825 )
    14.72 ( 4.613 )
    21.04 ( 17.138 )
        CD45+CD3-CD56+CD16+CD107+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    60.94 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD56+CD16+CD107+; D29; n=1,3,1,4,4,8
    16.53 ( 99999 )
    8.01 ( 4.316 )
    50.92 ( 99999 )
    15.68 ( 2.613 )
    25.75 ( 9.873 )
    18.09 ( 7.210 )
        CD45+CD3-CD56+CD16+CD107+; FU; n=1,2,0,3,1,4
    13.70 ( 99999 )
    19.58 ( 14.078 )
    99999 ( 99999 )
    29.76 ( 28.400 )
    11.68 ( 99999 )
    25.61 ( 14.702 )
        CD45+CD3-CD56+CD16+CD107+; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    16.42 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CDX241; D1;pre; n=1,3,1,5,4,9
    6.63 ( 99999 )
    12.09 ( 5.664 )
    16.96 ( 99999 )
    17.32 ( 13.319 )
    22.27 ( 11.808 )
    22.97 ( 31.676 )
        CDX241; D1;1h;n=1,3,1,5,4,9
    12.01 ( 99999 )
    14.02 ( 7.382 )
    7.34 ( 99999 )
    19.15 ( 13.818 )
    23.12 ( 14.060 )
    20.23 ( 26.492 )
        CDX241; D1;6h;n=1,3,1,5,4,11
    15.03 ( 99999 )
    14.75 ( 6.934 )
    31.75 ( 99999 )
    27.46 ( 16.219 )
    20.23 ( 12.033 )
    19.06 ( 18.044 )
        CDX241; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    25.26 ( 99999 )
    31.68 ( 10.769 )
    99999 ( 99999 )
    29.94 ( 99999 )
        CDX241; D8; n=1,3,0,5,4,8
    32.10 ( 99999 )
    6.47 ( 3.238 )
    99999 ( 99999 )
    18.50 ( 9.029 )
    13.88 ( 2.075 )
    26.20 ( 33.362 )
        CDX241; D15;S1;n=1,3,1,5,4,9
    15.97 ( 99999 )
    6.13 ( 3.908 )
    40.38 ( 99999 )
    14.62 ( 8.827 )
    14.55 ( 4.521 )
    20.62 ( 17.353 )
        CDX241; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    60.94 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CDX241; D29; n=1,3,1,4,4,8
    15.99 ( 99999 )
    8.01 ( 4.316 )
    49.39 ( 99999 )
    15.40 ( 2.640 )
    25.56 ( 9.917 )
    16.64 ( 6.597 )
        CDX241; FU; n=1,2,0,3,1,4
    13.66 ( 99999 )
    19.29 ( 13.668 )
    99999 ( 99999 )
    29.58 ( 28.512 )
    11.59 ( 99999 )
    25.41 ( 14.820 )
        CDX241; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    15.64 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CDX243; D1; pre; n=1,3,1,5,4,9
    61.33 ( 99999 )
    67.54 ( 8.092 )
    66.96 ( 99999 )
    63.34 ( 9.199 )
    60.08 ( 11.697 )
    52.56 ( 22.645 )
        CDX243; D1;1h; n=1,3,1,5,4,9
    64.84 ( 99999 )
    65.31 ( 7.929 )
    80.73 ( 99999 )
    62.49 ( 8.086 )
    62.45 ( 11.395 )
    57.22 ( 19.058 )
        CDX243;D1;6h; n=1,3,1,5,4,11
    63.21 ( 99999 )
    61.93 ( 9.710 )
    61.90 ( 99999 )
    55.89 ( 11.139 )
    63.72 ( 9.993 )
    59.86 ( 14.378 )
        CDX243; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    65.26 ( 99999 )
    57.46 ( 13.909 )
    99999 ( 99999 )
    57.96 ( 99999 )
        CDX243; D8; n=1,3,0,5,4,8
    44.92 ( 99999 )
    68.91 ( 8.623 )
    99999 ( 99999 )
    62.04 ( 7.093 )
    65.87 ( 2.821 )
    44.43 ( 22.911 )
        CDX243; D15;S1; n=1,3,1,5,4,9
    65.55 ( 99999 )
    72.34 ( 0.958 )
    56.73 ( 99999 )
    65.32 ( 4.554 )
    66.13 ( 9.524 )
    58.47 ( 16.070 )
        CDX243; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    33.48 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CDX243; D29; n=1,3,1,4,4,8
    62.99 ( 99999 )
    73.88 ( 3.073 )
    36.50 ( 99999 )
    64.75 ( 5.261 )
    56.80 ( 5.697 )
    57.98 ( 21.467 )
        CDX243; FU;n=1,2,0,3,1,4
    63.77 ( 99999 )
    64.51 ( 15.146 )
    99999 ( 99999 )
    51.52 ( 18.071 )
    65.13 ( 99999 )
    55.52 ( 9.421 )
        CDX243; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    49.72 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CDX244; D1; pre; n=1,3,1,5,4,9
    0.18 ( 99999 )
    0.08 ( 0.139 )
    0.00 ( 99999 )
    0.23 ( 0.289 )
    0.45 ( 0.422 )
    0.21 ( 0.505 )
        CDX244; D1;1h;n=1,3,1,5,4,9
    0.39 ( 99999 )
    0.35 ( 0.454 )
    0.00 ( 99999 )
    0.09 ( 0.137 )
    0.22 ( 0.391 )
    0.17 ( 0.319 )
        CDX244; D1;6h;n=1,3,1,5,4,11
    0.00 ( 99999 )
    0.11 ( 0.191 )
    0.00 ( 99999 )
    0.06 ( 0.089 )
    0.24 ( 0.423 )
    0.30 ( 0.682 )
        CDX244; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    0.00 ( 99999 )
    0.57 ( 0.799 )
    99999 ( 99999 )
    0.64 ( 99999 )
        CDX244; D8; n=1,3,0,5,4,8
    0.98 ( 99999 )
    0.06 ( 0.110 )
    99999 ( 99999 )
    0.08 ( 0.116 )
    0.02 ( 0.045 )
    0.49 ( 0.601 )
        CDX244; D15;S1;n=1,3,1,5,4,9
    0.26 ( 99999 )
    0.07 ( 0.115 )
    0.00 ( 99999 )
    1.53 ( 99999 )
    0.71 ( 0.204 )
    0.42 ( 0.632 )
        CDX244; D15;S2n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    0.00 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CDX244; D29; n=1,3,1,4,4,8
    0.54 ( 99999 )
    0.00 ( 0.000 )
    1.53 ( 99999 )
    0.28 ( 0.392 )
    0.19 ( 0.194 )
    1.46 ( 1.849 )
        CDX244; FU;n=1,2,0,3,1,4
    0.04 ( 99999 )
    0.29 ( 0.410 )
    99999 ( 99999 )
    0.18 ( 0.267 )
    0.09 ( 99999 )
    0.20 ( 0.189 )
        CDX244; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    0.79 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CDX245; D1; pre; n=1,3,1,5,4,9
    31.86 ( 99999 )
    20.28 ( 3.144 )
    16.07 ( 99999 )
    19.11 ( 7.819 )
    17.21 ( 3.797 )
    24.26 ( 16.218 )
        CDX245; D1; 1h; n=1,3,1,5,4,9
    22.75 ( 99999 )
    20.32 ( 2.902 )
    11.93 ( 99999 )
    18.27 ( 9.233 )
    14.21 ( 3.682 )
    22.37 ( 17.894 )
        CDX245; D1; 6h; n=1,3,1,5,4,11
    21.76 ( 99999 )
    23.22 ( 11.931 )
    6.35 ( 99999 )
    16.59 ( 5.742 )
    15.82 ( 4.876 )
    20.79 ( 12.726 )
        CDX245; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    9.47 ( 99999 )
    10.31 ( 3.946 )
    99999 ( 99999 )
    11.46 ( 99999 )
        CDX245; D8; n=1,3,0,5,4,8
    22.00 ( 99999 )
    24.56 ( 5.547 )
    99999 ( 99999 )
    19.37 ( 10.290 )
    20.23 ( 1.977 )
    28.88 ( 21.510 )
        CDX245; D15; S1; n=1,3,1,5,4,9
    18.22 ( 99999 )
    21.46 ( 3.242 )
    2.88 ( 99999 )
    20.00 ( 6.887 )
    19.16 ( 5.695 )
    20.48 ( 19.116 )
        CDX245; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    5.58 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CDX245; D29; n=1,3,1,4,4,8
    20.48 ( 99999 )
    18.10 ( 2.566 )
    12.58 ( 99999 )
    19.57 ( 7.550 )
    17.45 ( 4.991 )
    23.93 ( 16.995 )
        CDX245; FU; n=1,2,0,3,1,4
    22.53 ( 99999 )
    15.91 ( 1.075 )
    99999 ( 99999 )
    18.72 ( 12.153 )
    23.19 ( 99999 )
    18.88 ( 18.996 )
        CDX245; USC; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    33.86 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69+;D1pre; n=1,3,1,5,4,9
    62.80 ( 99999 )
    77.83 ( 5.748 )
    84.62 ( 99999 )
    76.05 ( 13.328 )
    80.50 ( 5.553 )
    72.52 ( 20.777 )
        CD45+CD3+CD56+CD69+;D1;1 h;n=1,3,1,5,4,9
    71.21 ( 99999 )
    77.91 ( 8.757 )
    100.00 ( 99999 )
    74.68 ( 12.530 )
    76.76 ( 7.819 )
    69.96 ( 23.711 )
        CD45+CD3+CD56+CD69+;D1;6 h;n=1,3,1,5,4,11
    77.14 ( 99999 )
    76.55 ( 11.000 )
    100.00 ( 99999 )
    75.64 ( 10.831 )
    77.96 ( 9.405 )
    73.92 ( 20.707 )
        CD45+CD3+CD56+CD69+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    90.00 ( 99999 )
    79.51 ( 11.823 )
    99999 ( 99999 )
    81.34 ( 99999 )
        CD45+CD3+CD56+CD69+; D8; n=1,3,0,5,4,8
    70.35 ( 99999 )
    79.41 ( 6.359 )
    99999 ( 99999 )
    77.26 ( 8.083 )
    77.76 ( 3.671 )
    71.42 ( 17.583 )
        CD45+CD3+CD56+CD69+; D15;S1; n=1,3,1,5,4,9
    76.53 ( 99999 )
    81.26 ( 7.195 )
    100 ( 99999 )
    76.72 ( 9.716 )
    75.78 ( 3.311 )
    72.29 ( 22.078 )
        CD45+CD3+CD56+CD69+;D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    90.91 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69+; D29; n=1,3,1,4,4,8
    76.53 ( 99999 )
    84.46 ( 9.848 )
    92.11 ( 99999 )
    75.11 ( 5.695 )
    79.47 ( 4.516 )
    73.25 ( 19.837 )
        CD45+CD3+CD56+CD69+; FU;n=1,2,0,3,1,4
    76.95 ( 99999 )
    83.76 ( 2.977 )
    99999 ( 99999 )
    76.93 ( 2.841 )
    78.84 ( 99999 )
    78.73 ( 13.208 )
        CD45+CD3+CD56+CD69+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    73.08 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD107+;D1pre; n=1,3,1,5,4,9
    8.10 ( 99999 )
    23.44 ( 3.025 )
    30.77 ( 99999 )
    24.69 ( 14.219 )
    25.59 ( 10.582 )
    21.94 ( 11.569 )
        CD45+CD3+CD56+CD107+;D1;1 h;n=1,3,1,5,4,9
    16.16 ( 99999 )
    25.59 ( 8.435 )
    16.67 ( 99999 )
    25.84 ( 13.782 )
    20.17 ( 7.408 )
    19.38 ( 9.838 )
        CD45+CD3+CD56+CD107+;D1;6 h;n=1,3,1,5,4,11
    17.14 ( 99999 )
    27.55 ( 9.084 )
    77.27 ( 99999 )
    25.54 ( 14.785 )
    18.38 ( 7.558 )
    27.83 ( 16.580 )
        CD45+CD3+CD56+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    50.00 ( 99999 )
    12.40 ( 2.892 )
    99999 ( 99999 )
    21.27 ( 99999 )
        CD45+CD3+CD56+CD107+; D8; n=1,3,0,5,4,8
    34.51 ( 99999 )
    25.08 ( 12.140 )
    99999 ( 99999 )
    22.70 ( 6.042 )
    23.85 ( 15.031 )
    25.37 ( 9.055 )
        CD45+CD3+CD56+CD107+; D15; S1;n=1,3,1,5,4,9
    24.44 ( 99999 )
    16.39 ( 9.804 )
    66.67 ( 99999 )
    20.15 ( 15.543 )
    22.75 ( 9.361 )
    24.77 ( 13.389 )
        CD45+CD3+CD56+CD107+;D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    91.36 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD107+; D29; n=1,3,1,4,4,8
    19.20 ( 99999 )
    24.61 ( 12.809 )
    94.74 ( 99999 )
    21.97 ( 16.720 )
    26.64 ( 16.501 )
    25.47 ( 7.825 )
        CD45+CD3+CD56+CD107+; FU;n=1,2,0,3,1,4
    19.60 ( 99999 )
    27.79 ( 8.132 )
    99999 ( 99999 )
    32.87 ( 23.340 )
    16.40 ( 99999 )
    26.92 ( 16.312 )
        CD45+CD3+CD56+CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    20.51 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69+CD107+;D1;pre; n=1,3,1,5,4,9
    8.10 ( 99999 )
    23.26 ( 2.974 )
    30.77 ( 99999 )
    23.85 ( 14.628 )
    24.97 ( 10.148 )
    21.16 ( 11.995 )
        CD45+CD3+CD56+CD69+CD107+;D1;1 h;n=1,3,1,5,4,9
    15.15 ( 99999 )
    25.29 ( 8.566 )
    16.67 ( 99999 )
    24.96 ( 14.211 )
    19.58 ( 6.559 )
    18.93 ( 9.947 )
        CD45+CD3+CD56+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
    17.14 ( 99999 )
    26.84 ( 8.938 )
    77.27 ( 99999 )
    24.77 ( 15.022 )
    17.89 ( 7.034 )
    26.49 ( 16.563 )
        CD45+CD3+CD56+CD69+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    50.00 ( 99999 )
    12.24 ( 3.111 )
    99999 ( 99999 )
    20.90 ( 99999 )
        CD45+CD3+CD56+CD69+CD107+; D8; n=1,3,0,5,4,8
    32.08 ( 99999 )
    24.24 ( 11.427 )
    99999 ( 99999 )
    22.33 ( 5.946 )
    23.10 ( 14.534 )
    24.68 ( 9.353 )
        CD45+CD3+CD56+CD69+CD107+; D15;S1; n=1,3,1,5,4,9
    24.12 ( 99999 )
    16.22 ( 9.646 )
    66.67 ( 99999 )
    19.78 ( 15.294 )
    22.25 ( 9.194 )
    23.91 ( 13.531 )
        CD45+CD3+CD56+CD69+CD107+;D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    85.45 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69+CD107+; D29; n=1,3,1,4,4,8
    18.67 ( 99999 )
    24.31 ( 12.597 )
    86.84 ( 99999 )
    21.41 ( 16.520 )
    25.87 ( 15.887 )
    23.72 ( 7.717 )
        CD45+CD3+CD56+CD69+CD107+; FU;n=1,2,0,3,1,4
    19.60 ( 99999 )
    27.48 ( 8.217 )
    99999 ( 99999 )
    31.89 ( 22.622 )
    15.87 ( 99999 )
    26.51 ( 16.034 )
        CD45+CD3+CD56+CD69+CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    16.67 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69+CD107-;D1; pre; n=1,3,1,5,4,9
    54.70 ( 99999 )
    54.57 ( 2.810 )
    53.85 ( 99999 )
    52.20 ( 11.519 )
    55.53 ( 15.219 )
    51.35 ( 15.196 )
        CD45+CD3+CD56+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9
    56.06 ( 99999 )
    52.62 ( 3.308 )
    83.33 ( 99999 )
    49.72 ( 10.923 )
    57.19 ( 10.200 )
    51.04 ( 17.281 )
        CD45+CD3+CD56+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
    60.00 ( 99999 )
    49.71 ( 2.501 )
    22.73 ( 99999 )
    50.88 ( 11.326 )
    60.07 ( 13.763 )
    47.43 ( 15.287 )
        CD45+CD3+CD56+CD69+CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    40.00 ( 99999 )
    67.28 ( 8.719 )
    99999 ( 99999 )
    60.45 ( 99999 )
        CD45+CD3+CD56+CD69+CD107-; D8; n=1,3,0,5,4,8
    38.27 ( 99999 )
    55.17 ( 6.740 )
    99999 ( 99999 )
    54.92 ( 10.367 )
    54.67 ( 12.323 )
    46.74 ( 9.237 )
        CD45+CD3+CD56+CD69+CD107-; D15;S1; n=1,3,1,5,4,9
    52.41 ( 99999 )
    65.04 ( 6.660 )
    33.33 ( 99999 )
    56.94 ( 9.081 )
    53.53 ( 10.408 )
    48.38 ( 17.947 )
        CD45+CD3+CD56+CD69+CD107-;D15;S2;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    5.45 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69+CD107-; D29; n=1,3,1,4,4,8
    57.87 ( 99999 )
    60.14 ( 4.928 )
    5.26 ( 99999 )
    53.70 ( 12.139 )
    53.61 ( 15.433 )
    49.53 ( 16.556 )
        CD45+CD3+CD56+CD69+CD107-; FU;n=1,2,0,3,1,4
    57.35 ( 99999 )
    56.28 ( 5.240 )
    99999 ( 99999 )
    45.05 ( 22.028 )
    62.96 ( 99999 )
    52.22 ( 5.130 )
        CD45+CD3+CD56+CD69+CD107-; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    56.41 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69-CD107+;D1pre; n=1,3,1,5,4,9
    0.00 ( 99999 )
    0.19 ( 0.163 )
    0.00 ( 99999 )
    0.84 ( 1.119 )
    0.62 ( 0.761 )
    0.77 ( 1.157 )
        CD45+CD3+CD56+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9
    1.01 ( 99999 )
    0.30 ( 0.295 )
    0.00 ( 99999 )
    0.87 ( 1.493 )
    0.59 ( 0.889 )
    0.45 ( 0.501 )
        CD45+CD3+CD56+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
    0.00 ( 99999 )
    0.72 ( 0.806 )
    0.00 ( 99999 )
    0.77 ( 1.369 )
    0.49 ( 0.666 )
    1.35 ( 2.225 )
        CD45+CD3+CD56+CD69-CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    0.00 ( 99999 )
    0.16 ( 0.219 )
    99999 ( 99999 )
    0.37 ( 99999 )
        CD45+CD3+CD56+CD69-CD107+; D8; n=1,3,0,5,4,8
    2.43 ( 99999 )
    0.84 ( 0.716 )
    99999 ( 99999 )
    0.37 ( 0.613 )
    0.75 ( 0.573 )
    0.69 ( 0.656 )
        CD45+CD3+CD56+CD69-CD107+; D15;S1;n=1,3,1,5,4,9
    0.32 ( 99999 )
    0.17 ( 0.300 )
    0.00 ( 99999 )
    0.37 ( 0.288 )
    0.51 ( 0.307 )
    0.87 ( 1.194 )
        CD45+CD3+CD56+CD69-CD107+;D15;S2;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    5.91 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69-CD107+; D29; n=1,3,1,4,4,8
    0.53 ( 99999 )
    0.29 ( 0.409 )
    7.89 ( 99999 )
    0.57 ( 0.312 )
    0.77 ( 0.697 )
    1.75 ( 2.925 )
        CD45+CD3+CD56+CD69-CD107+; FU;n=1,2,0,3,1,4
    0.00 ( 99999 )
    0.31 ( 0.085 )
    99999 ( 99999 )
    0.98 ( 1.235 )
    0.53 ( 99999 )
    0.41 ( 0.407 )
        CD45+CD3+CD56+CD69-CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    3.85 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69-CD107-;D1pre; n=1,3,1,5,4,9
    37.20 ( 99999 )
    21.98 ( 5.814 )
    15.38 ( 99999 )
    23.11 ( 12.486 )
    18.88 ( 5.007 )
    26.71 ( 19.740 )
        CD45+CD3+CD56+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9
    27.78 ( 99999 )
    21.78 ( 8.736 )
    0.00 ( 99999 )
    24.444 ( 11.410 )
    22.65 ( 7.631 )
    29.59 ( 23.473 )
        CD45+CD3+CD56+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
    22.86 ( 99999 )
    22.74 ( 11.250 )
    0.00 ( 99999 )
    23.59 ( 9.836 )
    21.55 ( 8.954 )
    24.74 ( 19.457 )
        CD45+CD3+CD56+CD69-CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    10.00 ( 99999 )
    20.34 ( 11.604 )
    99999 ( 99999 )
    18.28 ( 99999 )
        CD45+CD3+CD56+CD69-CD107-; D8; n=1,3,0,5,4,8
    27.21 ( 99999 )
    19.75 ( 7.018 )
    99999 ( 99999 )
    22.38 ( 7.709 )
    21.49 ( 4.140 )
    27.89 ( 17.180 )
        CD45+CD3+CD56+CD69-CD107-; D15;S1; n=1,3,1,5,4,9
    23.15 ( 99999 )
    18.56 ( 7.134 )
    0.00 ( 99999 )
    22.91 ( 9.852 )
    23.72 ( 3.040 )
    26.84 ( 21.388 )
        CD45+CD3+CD56+CD69-CD107-;D15;S2;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    3.18 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD56+CD69-CD107-; D29; n=1,3,1,4,4,8
    22.93 ( 99999 )
    15.25 ( 9.918 )
    0.00 ( 99999 )
    24.33 ( 5.914 )
    19.76 ( 4.920 )
    25.00 ( 18.022 )
        CD45+CD3+CD56+CD69-CD107-; FU;n=1,2,0,3,1,4
    23.05 ( 99999 )
    15.94 ( 2.892 )
    99999 ( 99999 )
    22.09 ( 2.249 )
    20.63 ( 99999 )
    20.86 ( 13.394 )
        CD45+CD3+CD56+CD69-CD107-; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    23.08 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69+;D1pre; n=1,3,1,5,4,9
    57.87 ( 99999 )
    71.12 ( 1.083 )
    59.62 ( 99999 )
    70.19 ( 9.089 )
    69.48 ( 7.473 )
    64.41 ( 15.841 )
        CD45+CD3+CD8+CD69+;D1;1 h;n=1,3,1,5,4,9
    54.45 ( 99999 )
    66.55 ( 0.781 )
    66.67 ( 99999 )
    68.39 ( 8.060 )
    69.27 ( 10.664 )
    62.62 ( 18.568 )
        CD45+CD3+CD8+CD69+;D1;6 h;n=1,3,1,5,4,11
    70.17 ( 99999 )
    64.77 ( 2.867 )
    81.08 ( 99999 )
    67.66 ( 7.411 )
    69.44 ( 10.476 )
    64.10 ( 16.568 )
        CD45+CD3+CD8+CD69+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    71.67 ( 99999 )
    77.60 ( 7.898 )
    99999 ( 99999 )
    73.16 ( 99999 )
        CD45+CD3+CD8+CD69+; D8; n=1,3,0,5,4,8
    63.60 ( 99999 )
    65.38 ( 2.682 )
    99999 ( 99999 )
    71.51 ( 5.945 )
    69.15 ( 2.032 )
    59.81 ( 14.230 )
        CD45+CD3+CD8+CD69+; D15;S1; n=1,3,1,5,4,9
    66.21 ( 99999 )
    70.12 ( 3.641 )
    67.74 ( 99999 )
    72.11 ( 5.807 )
    65.46 ( 2.301 )
    58.44 ( 20.646 )
        CD45+CD3+CD8+CD69+; D15;S2;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    69.60 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69+; D29; n=1,3,1,4,4,8
    68.47 ( 99999 )
    72.13 ( 0.599 )
    52.66 ( 99999 )
    68.07 ( 4.666 )
    70.42 ( 3.658 )
    60.96 ( 16.314 )
        CD45+CD3+CD8+CD69+; FU;n=1,2,0,3,1,4
    67.97 ( 99999 )
    74.76 ( 3.903 )
    99999 ( 99999 )
    74.36 ( 3.927 )
    70.80 ( 99999 )
    70.63 ( 13.052 )
        CD45+CD3+CD8+CD69+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    45.15 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD107+;D1pre; n=1,3,1,5,4,9
    9.25 ( 99999 )
    24.58 ( 6.553 )
    17.31 ( 99999 )
    24.38 ( 10.840 )
    19.50 ( 5.678 )
    12.96 ( 7.622 )
        CD45+CD3+CD8+CD107+;D1;1 h;n=1,3,1,5,4,9
    11.02 ( 99999 )
    21.64 ( 7.885 )
    4.17 ( 99999 )
    24.87 ( 10.264 )
    17.86 ( 7.915 )
    12.10 ( 9.816 )
        CD45+CD3+CD8+CD107+;D1;6 h;n=1,3,1,5,4,11
    13.88 ( 99999 )
    22.21 ( 5.668 )
    35.14 ( 99999 )
    21.61 ( 12.241 )
    17.74 ( 6.679 )
    14.58 ( 7.973 )
        CD45+CD3+CD8+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    25.00 ( 99999 )
    17.03 ( 4.907 )
    99999 ( 99999 )
    15.65 ( 99999 )
        CD45+CD3+CD8+CD107+; D8; n=1,3,0,5,4,8
    37.70 ( 99999 )
    19.18 ( 3.660 )
    99999 ( 99999 )
    24.12 ( 11.200 )
    19.58 ( 10.034 )
    13.53 ( 7.177 )
        CD45+CD3+CD8+CD107+; D15; S1;n=1,3,1,5,4,9
    20.58 ( 99999 )
    11.59 ( 2.973 )
    93.55 ( 99999 )
    21.11 ( 14.964 )
    18.52 ( 6.515 )
    14.52 ( 11.560 )
        CD45+CD3+CD8+CD107+; D15;S2;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    90.12 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD107+; D29; n=1,3,1,4,4,8
    44.48 ( 99999 )
    18.53 ( 2.105 )
    66.27 ( 99999 )
    18.44 ( 12.685 )
    22.28 ( 10.800 )
    16.01 ( 7.377 )
        CD45+CD3+CD8+CD107+; FU;n=1,2,0,3,1,4
    21.17 ( 99999 )
    23.00 ( 7.545 )
    99999 ( 99999 )
    34.50 ( 27.190 )
    20.65 ( 99999 )
    24.54 ( 20.530 )
        CD45+CD3+CD8+CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    13.91 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69+CD107+;D1pre; n=1,3,1,5,4,9
    8.95 ( 99999 )
    23.82 ( 6.136 )
    16.35 ( 99999 )
    23.35 ( 10.595 )
    18.89 ( 5.513 )
    12.42 ( 7.519 )
        CD45+CD3+CD8+CD69+CD107+;D1;1 h;n=1,3,1,5,4,9
    10.13 ( 99999 )
    20.60 ( 7.232 )
    4.17 ( 99999 )
    23.63 ( 10.069 )
    17.10 ( 7.592 )
    11.51 ( 9.671 )
        CD45+CD3+CD8+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
    13.70 ( 99999 )
    20.92 ( 4.681 )
    35.14 ( 99999 )
    20.61 ( 11.463 )
    16.83 ( 6.502 )
    13.49 ( 8.242 )
        CD45+CD3+CD8+CD69+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    25.00 ( 99999 )
    16.67 ( 4.391 )
    99999 ( 99999 )
    15.59 ( 99999 )
        CD45+CD3+CD8+CD69+CD107+; D8; n=1,3,0,5,4,8
    33.65 ( 99999 )
    17.86 ( 1.989 )
    99999 ( 99999 )
    23.15 ( 10.176 )
    18.62 ( 9.229 )
    12.58 ( 6.811 )
        CD45+CD3+CD8+CD69+CD107+; D15;S1; n=1,3,1,5,4,9
    19.35 ( 99999 )
    11.35 ( 2.815 )
    64.52 ( 99999 )
    20.62 ( 14.511 )
    17.46 ( 5.818 )
    13.79 ( 11.461 )
        CD45+CD3+CD8+CD69+CD107+; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    66.74 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69+CD107+; D29; n=1,3,1,4,4,8
    36.62 ( 99999 )
    18.16 ( 2.172 )
    44.97 ( 99999 )
    17.79 ( 12.221 )
    21.18 ( 9.942 )
    14.79 ( 7.086 )
        CD45+CD3+CD8+CD69+CD107+; FU;n=1,2,0,3,1,4
    20.35 ( 99999 )
    22.43 ( 7.177 )
    99999 ( 99999 )
    33.05 ( 25.896 )
    20.35 ( 99999 )
    22.91 ( 18.370 )
        CD45+CD3+CD8+CD69+CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    12.34 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69+CD107-;D1pre; n=1,3,1,5,4,9
    48.92 ( 99999 )
    47.30 ( 5.590 )
    43.27 ( 99999 )
    46.85 ( 9.558 )
    50.59 ( 11.155 )
    51.99 ( 13.129 )
        CD45+CD3+CD8+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9
    44.32 ( 99999 )
    45.95 ( 6.784 )
    62.50 ( 99999 )
    44.76 ( 7.470 )
    52.17 ( 7.570 )
    51.12 ( 15.653 )
        CD45+CD3+CD8+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
    56.47 ( 99999 )
    43.85 ( 7.548 )
    45.95 ( 99999 )
    47.05 ( 7.908 )
    52.61 ( 7.942 )
    50.61 ( 11.996 )
        CD45+CD3+CD8+CD69+CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    46.67 ( 99999 )
    60.93 ( 12.282 )
    99999 ( 99999 )
    57.57 ( 99999 )
        CD45+CD3+CD8+CD69+CD107-; D8; n=1,3,0,5,4,8
    29.96 ( 99999 )
    47.53 ( 4.483 )
    99999 ( 99999 )
    48.36 ( 11.067 )
    50.52 ( 8.995 )
    47.22 ( 12.334 )
        CD45+CD3+CD8+CD69+CD107-; D15; S1;n=1,3,1,5,4,9
    46.86 ( 99999 )
    58.77 ( 6.439 )
    3.23 ( 99999 )
    51.49 ( 9.965 )
    47.99 ( 7.314 )
    44.65 ( 18.062 )
        CD45+CD3+CD8+CD69+CD107-; D15; S2;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    2.86 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69+CD107-; D29; n=1,3,1,4,4,8
    31.86 ( 99999 )
    53.96 ( 1.639 )
    7.69 ( 99999 )
    50.28 ( 9.182 )
    49.25 ( 12.319 )
    46.17 ( 14.907 )
        CD45+CD3+CD8+CD69+CD107-; FU;n=1,2,0,3,1,4
    47.63 ( 99999 )
    52.34 ( 3.274 )
    99999 ( 99999 )
    41.31 ( 23.301 )
    50.44 ( 99999 )
    47.72 ( 13.474 )
        CD45+CD3+CD8+CD69+CD107-; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    32.81 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69-CD107+;D1pre; n=1,3,1,5,4,9
    0.30 ( 99999 )
    0.76 ( 0.475 )
    0.96 ( 99999 )
    1.03 ( 1.228 )
    0.61 ( 0.493 )
    0.54 ( 0.575 )
        CD45+CD3+CD8+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9
    0.89 ( 99999 )
    1.03 ( 0.683 )
    0.00 ( 99999 )
    1.24 ( 1.342 )
    0.76 ( 0.919 )
    0.59 ( 0.605 )
        CD45+CD3+CD8+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
    0.19 ( 99999 )
    1.30 ( 1.040 )
    0.00 ( 99999 )
    1.01 ( 1.572 )
    0.91 ( 0.629 )
    1.09 ( 1.070 )
        CD45+CD3+CD8+CD69-CD107+; D8; n=1,3,0,5,4,8
    4.05 ( 99999 )
    1.32 ( 1.711 )
    99999 ( 99999 )
    0.97 ( 1.172 )
    0.96 ( 1.007 )
    0.95 ( 1.058 )
        CD45+CD3+CD8+CD69-CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    0.00 ( 99999 )
    0.37 ( 0.516 )
    99999 ( 99999 )
    0.06 ( 99999 )
        CD45+CD3+CD8+CD69-CD107+; D15;S1;n=1,3,1,5,4,9
    1.23 ( 99999 )
    0.24 ( 0.163 )
    29.03 ( 99999 )
    0.48 ( 0.609 )
    1.05 ( 0.920 )
    0.73 ( 0.435 )
        CD45+CD3+CD8+CD69-CD107+; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    23.37 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69-CD107+; D29; n=1,3,1,4,4,8
    7.87 ( 99999 )
    0.37 ( 0.078 )
    21.30 ( 99999 )
    0.65 ( 0.554 )
    1.10 ( 0.919 )
    1.22 ( 1.347 )
        CD45+CD3+CD8+CD69-CD107+; FU;n=1,2,0,3,1,4
    0.82 ( 99999 )
    0.58 ( 0.361 )
    99999 ( 99999 )
    1.44 ( 1.298 )
    0.29 ( 99999 )
    1.63 ( 2.326 )
        CD45+CD3+CD8+CD69-CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    1.57 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69-CD107-;D1pre; n=1,3,1,5,4,9
    41.83 ( 99999 )
    28.12 ( 1.219 )
    39.42 ( 99999 )
    28.78 ( 8.425 )
    29.92 ( 7.082 )
    35.04 ( 15.444 )
        CD45+CD3+CD8+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9
    44.65 ( 99999 )
    32.42 ( 1.397 )
    33.33 ( 99999 )
    30.37 ( 7.516 )
    29.97 ( 10.290 )
    36.79 ( 18.243 )
        CD45+CD3+CD8+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
    29.64 ( 99999 )
    33.94 ( 1.914 )
    18.92 ( 99999 )
    31.34 ( 7.255 )
    29.65 ( 10.132 )
    34.81 ( 15.738 )
        CD45+CD3+CD8+CD69-CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    28.33 ( 99999 )
    22.04 ( 7.382 )
    99999 ( 99999 )
    26.77 ( 99999 )
        CD45+CD3+CD8+CD69-CD107-; D8; n=1,3,0,5,4,8
    32.34 ( 99999 )
    33.30 ( 2.044 )
    99999 ( 99999 )
    27.52 ( 6.239 )
    29.90 ( 2.006 )
    39.24 ( 13.864 )
        CD45+CD3+CD8+CD69-CD107-; D15;S1; n=1,3,1,5,4,9
    32.56 ( 99999 )
    29.64 ( 3.488 )
    3.23 ( 99999 )
    27.41 ( 6.016 )
    33.49 ( 1.695 )
    40.83 ( 20.434 )
        CD45+CD3+CD8+CD69-CD107-; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    7.03 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8+CD69-CD107-; D29; n=1,3,1,4,4,8
    23.66 ( 99999 )
    27.50 ( 0.558 )
    26.04 ( 99999 )
    31.28 ( 4.954 )
    28.48 ( 3.302 )
    37.82 ( 15.640 )
        CD45+CD3+CD8+CD69-CD107-; FU;n=1,2,0,3,1,4
    31.20 ( 99999 )
    24.67 ( 4.264 )
    99999 ( 99999 )
    24.19 ( 5.014 )
    28.91 ( 99999 )
    27.74 ( 14.176 )
        CD45+CD3+CD8+CD69-CD107-; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    53.28 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69+;D1pre; n=1,3,1,5,4,9
    49.72 ( 99999 )
    64.40 ( 2.410 )
    61.84 ( 99999 )
    64.96 ( 9.980 )
    63.78 ( 9.470 )
    57.37 ( 19.984 )
        CD45+CD3+CD69+;D1;1 h;n=1,3,1,5,4,9
    50.16 ( 99999 )
    60.66 ( 4.707 )
    67.16 ( 99999 )
    63.58 ( 8.122 )
    62.71 ( 13.023 )
    55.80 ( 21.386 )
        CD45+CD3+CD69+;D1;6 h;n=1,3,1,5,4,11
    63.54 ( 99999 )
    61.49 ( 3.426 )
    80.00 ( 99999 )
    62.24 ( 7.910 )
    63.26 ( 12.922 )
    60.07 ( 19.171 )
        CD45+CD3+CD69+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    68.61 ( 99999 )
    69.01 ( 3.783 )
    99999 ( 99999 )
    62.93 ( 99999 )
        CD45+CD3+CD69+; D8; n=1,3,0,5,4,8
    58.04 ( 99999 )
    59.29 ( 5.515 )
    99999 ( 99999 )
    64.97 ( 2.165 )
    65.73 ( 6.597 )
    51.29 ( 13.826 )
        CD45+CD3+CD69+; D15;S1; n=1,3,1,5,4,9
    53.90 ( 99999 )
    64.92 ( 4.016 )
    72.73 ( 99999 )
    65.08 ( 6.604 )
    58.46 ( 3.564 )
    53.38 ( 21.988 )
        CD45+CD3+CD69+; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    67.36 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69+; D29; n=1,3,1,4,4,8
    60.54 ( 99999 )
    67.97 ( 4.090 )
    52.79 ( 99999 )
    61.52 ( 6.451 )
    63.88 ( 5.978 )
    53.68 ( 19.308 )
        CD45+CD3+CD69+; FU;n=1,2,0,3,1,4
    54.72 ( 99999 )
    68.87 ( 8.259 )
    99999 ( 99999 )
    68.45 ( 0.841 )
    64.95 ( 99999 )
    67.21 ( 17.378 )
        CD45+CD3+CD69+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    42.30 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD107+;D1pre; n=1,3,1,5,4,9
    3.28 ( 99999 )
    13.70 ( 6.236 )
    11.66 ( 99999 )
    13.13 ( 10.732 )
    8.92 ( 4.982 )
    8.99 ( 4.894 )
        CD45+CD3+CD107+;D1;1 h;n=1,3,1,5,4,9
    3.17 ( 99999 )
    12.63 ( 8.846 )
    1.49 ( 99999 )
    12.84 ( 10.971 )
    6.79 ( 3.717 )
    7.91 ( 4.880 )
        CD45+CD3+CD107+;D1;6 h;n=1,3,1,5,4,11
    5.74 ( 99999 )
    11.98 ( 6.511 )
    24.50 ( 99999 )
    12.53 ( 10.804 )
    7.25 ( 3.529 )
    11.04 ( 4.474 )
        CD45+CD3+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    15.33 ( 99999 )
    6.17 ( 2.397 )
    99999 ( 99999 )
    9.61 ( 99999 )
        CD45+CD3+CD107+; D8; n=1,3,0,5,4,8
    19.48 ( 99999 )
    9.93 ( 4.733 )
    99999 ( 99999 )
    12.31 ( 7.851 )
    9.81 ( 6.276 )
    10.61 ( 7.576 )
        CD45+CD3+CD107+; D15;S1; n=1,3,1,5,4,9
    10.68 ( 99999 )
    4.32 ( 2.680 )
    76.14 ( 99999 )
    9.84 ( 7.608 )
    8.13 ( 4.504 )
    10.75 ( 6.692 )
        CD45+CD3+CD107+; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    84.64 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD107+; D29; n=1,3,1,4,4,8
    11.62 ( 99999 )
    9.24 ( 3.455 )
    54.47 ( 99999 )
    11.88 ( 12.246 )
    10.30 ( 6.320 )
    10.79 ( 4.881 )
        CD45+CD3+CD107+; FU;n=1,2,0,3,1,4
    6.07 ( 99999 )
    11.19 ( 6.124 )
    99999 ( 99999 )
    27.28 ( 11.058 )
    5.11 ( 99999 )
    12.44 ( 10.953 )
        CD45+CD3+CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    11.62 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69+CD107+;D1pre; n=1,3,1,5,4,9
    3.22 ( 99999 )
    13.33 ( 5.965 )
    11.31 ( 99999 )
    12.68 ( 10.738 )
    8.62 ( 4.781 )
    8.55 ( 4.996 )
        CD45+CD3+CD69+CD107+;D1;1 h;n=1,3,1,5,4,9
    3.04 ( 99999 )
    12.15 ( 8.408 )
    1.49 ( 99999 )
    12.33 ( 10.922 )
    6.42 ( 3.287 )
    7.43 ( 4.929 )
        CD45+CD3+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
    5.63 ( 99999 )
    11.29 ( 5.756 )
    24.50 ( 99999 )
    12.00 ( 10.573 )
    6.89 ( 3.217 )
    10.03 ( 4.618 )
        CD45+CD3+CD69+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    15.33 ( 99999 )
    6.02 ( 2.220 )
    99999 ( 99999 )
    9.57 ( 99999 )
        CD45+CD3+CD69+CD107+; D8; n=1,3,0,5,4,8
    17.91 ( 99999 )
    9.29 ( 3.881 )
    99999 ( 99999 )
    11.95 ( 7.603 )
    9.36 ( 5.904 )
    9.58 ( 6.752 )
        CD45+CD3+CD69+CD107+; D15;S1 ; n=1,3,1,5,4,9
    9.81 ( 99999 )
    4.25 ( 2.622 )
    62.5 ( 99999 )
    9.63 ( 7.568 )
    7.74 ( 4.077 )
    10.13 ( 6.879 )
        CD45+CD3+CD69+CD107+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    61.21 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69+CD107+; D29; n=1,3,1,4,4,8
    10.28 ( 99999 )
    9.07 ( 3.421 )
    40.50 ( 99999 )
    11.47 ( 11.821 )
    9.88 ( 5.888 )
    9.56 ( 4.499 )
        CD45+CD3+CD69+CD107+; FU;n=1,2,0,3,1,4
    5.92 ( 99999 )
    10.98 ( 5.961 )
    99999 ( 99999 )
    26.15 ( 10.446 )
    4.98 ( 99999 )
    11.70 ( 9.912 )
        CD45+CD3+CD69+CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    10.47 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69+CD107-;D1pre; n=1,3,1,5,4,9
    46.49 ( 99999 )
    51.06 ( 3.578 )
    50.53 ( 99999 )
    52.28 ( 8.029 )
    55.15 ( 13.699 )
    48.82 ( 16.871 )
        CD45+CD3+CD69+CD107-;D1;1 h;n=1,3,1,5,4,9
    47.13 ( 99999 )
    48.51 ( 4.092 )
    65.67 ( 99999 )
    51.25 ( 7.800 )
    56.29 ( 13.709 )
    48.37 ( 18.392 )
        CD45+CD3+CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
    57.91 ( 99999 )
    50.20 ( 6.989 )
    55.50 ( 99999 )
    50.24 ( 5.794 )
    56.37 ( 14.071 )
    50.04 ( 16.622 )
        CD45+CD3+CD69+CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    53.28 ( 99999 )
    62.99 ( 6.003 )
    99999 ( 99999 )
    53.35 ( 99999 )
        CD45+CD3+CD69+CD107-; D8; n=1,3,0,5,4,8
    40.13 ( 99999 )
    50.00 ( 5.550 )
    99999 ( 99999 )
    53.02 ( 7.641 )
    56.37 ( 8.661 )
    41.72 ( 11.909 )
        CD45+CD3+CD69+CD107-; D15; S1; n=1,3,1,5,4,9
    44.09 ( 99999 )
    60.67 ( 5.732 )
    10.23 ( 99999 )
    55.45 ( 4.502 )
    50.72 ( 6.589 )
    43.25 ( 18.831 )
        CD45+CD3+CD69+CD107-; D15; S2;n=0, 0, 1, 0, 0, 0
    99999 ( 99999 )
    99999 ( 99999 )
    6.15 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69+CD107-; D29; n=1,3,1,4,4,8
    50.26 ( 99999 )
    58.89 ( 0.756 )
    12.29 ( 99999 )
    50.05 ( 6.415 )
    54.00 ( 11.624 )
    44.11 ( 17.898 )
        CD45+CD3+CD69+CD107-; FU;n=1,2,0,3,1,4
    48.79 ( 99999 )
    57.90 ( 2.298 )
    99999 ( 99999 )
    42.29 ( 9.606 )
    59.97 ( 99999 )
    55.52 ( 16.825 )
        CD45+CD3+CD69+CD107-; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    31.83 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69-CD107+;D1pre; n=1,3,1,5,4,9
    0.06 ( 99999 )
    0.36 ( 0.277 )
    0.35 ( 99999 )
    0.45 ( 0.579 )
    0.30 ( 0.324 )
    0.44 ( 0.537 )
        CD45+CD3+CD69-CD107+;D1;1 h;n=1,3,1,5,4,9
    0.13 ( 99999 )
    0.47 ( 0.451 )
    0.00 ( 99999 )
    0.50 ( 0.615 )
    0.36 ( 0.477 )
    0.48 ( 0.459 )
        CD45+CD3+CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
    0.11 ( 99999 )
    0.69 ( 0.777 )
    0.00 ( 99999 )
    0.54 ( 0.844 )
    0.36 ( 0.349 )
    1.01 ( 1.233 )
        CD45+CD3+CD69-CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    0.00 ( 99999 )
    0.15 ( 0.177 )
    99999 ( 99999 )
    0.03 ( 99999 )
        CD45+CD3+CD69-CD107+; D8; n=1,3,0,5,4,8
    1.57 ( 99999 )
    0.64 ( 0.861 )
    99999 ( 99999 )
    0.35 ( 3.392 )
    0.45 ( 0.458 )
    1.04 ( 1.201 )
        CD45+CD3+CD69-CD107+; D15; S1; n=1,3,1,5,4,9
    0.86 ( 99999 )
    0.07 ( 0.059 )
    13.64 ( 99999 )
    0.21 ( 0.187 )
    0.39 ( 0.439 )
    0.62 ( 0.460 )
        CD45+CD3+CD69-CD107+; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    23.43 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69-CD107+; D29; n=1,3,1,4,4,8
    1.34 ( 99999 )
    0.17 ( 0.042 )
    13.97 ( 99999 )
    0.41 ( 0.476 )
    0.42 ( 0.449 )
    1.22 ( 1.608 )
        CD45+CD3+CD69-CD107+; FU;n=1,2,0,3,1,4
    0.15 ( 99999 )
    0.23 ( 0.163 )
    99999 ( 99999 )
    1.13 ( 0.705 )
    0.13 ( 99999 )
    0.75 ( 1.090 )
        CD45+CD3+CD69-CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    1.16 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69-CD107-;D1pre; n=1,3,1,5,4,9
    50.23 ( 99999 )
    35.23 ( 2.664 )
    37.81 ( 99999 )
    34.58 ( 9.638 )
    35.93 ( 9.242 )
    42.20 ( 19.537 )
        CD45+CD3+CD69-CD107-;D1;1 h;n=1,3,1,5,4,9
    49.71 ( 99999 )
    38.87 ( 5.156 )
    32.84 ( 99999 )
    35.91 ( 7.854 )
    36.93 ( 12.789 )
    43.72 ( 21.074 )
        CD45+CD3+CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
    36.35 ( 99999 )
    37.83 ( 3.625 )
    20.00 ( 99999 )
    37.23 ( 7.810 )
    36.38 ( 12.700 )
    38.92 ( 18.214 )
        CD45+CD3+CD69-CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    31.39 ( 99999 )
    30.85 ( 3.606 )
    99999 ( 99999 )
    37.04 ( 99999 )
        CD45+CD3+CD69-CD107-; D8; n=1,3,0,5,4,8
    40.39 ( 99999 )
    40.07 ( 5.758 )
    99999 ( 99999 )
    34.67 ( 2.320 )
    33.83 ( 6.576 )
    47.67 ( 13.646 )
        CD45+CD3+CD69-CD107-; D15;S1; n=1,3,1,5,4,9
    45.24 ( 99999 )
    35.01 ( 3.981 )
    13.64 ( 99999 )
    34.71 ( 6.524 )
    41.15 ( 3.409 )
    46.00 ( 21.556 )
        CD45+CD3+CD69-CD107-; D15; S2;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    9.2 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD69-CD107-; D29; n=1,3,1,4,4,8
    38.12 ( 99999 )
    31.87 ( 4.127 )
    33.24 ( 99999 )
    38.07 ( 6.801 )
    35.70 ( 5.601 )
    45.10 ( 18.361 )
        CD45+CD3+CD69-CD107-; FU;n=1,2,0,3,1,4
    45.14 ( 99999 )
    30.91 ( 8.422 )
    99999 ( 99999 )
    30.43 ( 1.483 )
    34.92 ( 99999 )
    32.05 ( 17.570 )
        CD45+CD3+CD69-CD107-; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    56.55 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69+;D1pre; n=1,3,1,5,4,9
    47.90 ( 99999 )
    61.18 ( 3.198 )
    63.79 ( 99999 )
    60.39 ( 9.372 )
    58.78 ( 9.546 )
    52.12 ( 20.035 )
        CD45+CD3+CD8-CD69+;D1;1 h;n=1,3,1,5,4,9
    49.15 ( 99999 )
    58.34 ( 5.829 )
    67.19 ( 99999 )
    60.93 ( 7.196 )
    59.04 ( 12.906 )
    51.86 ( 22.844 )
        CD45+CD3+CD8-CD69+;D1;6 h;n=1,3,1,5,4,11
    62.61 ( 99999 )
    60.24 ( 3.832 )
    77.59 ( 99999 )
    58.97 ( 6.452 )
    59.18 ( 13.744 )
    56.19 ( 18.029 )
        CD45+CD3+CD8-CD69+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    67.11 ( 99999 )
    63.36 ( 5.169 )
    99999 ( 99999 )
    51.49 ( 99999 )
        CD45+CD3+CD8-CD69+; D8; n=1,3,0,5,4,8
    57.28 ( 99999 )
    56.36 ( 7.227 )
    99999 ( 99999 )
    61.41 ( 3.385 )
    64.59 ( 10.317 )
    42.80 ( 13.006 )
        CD45+CD3+CD8-CD69+; D15; S1;n=1,3,1,5,4,9
    47.62 ( 99999 )
    64.16 ( 6.272 )
    75.86 ( 99999 )
    61.57 ( 4.769 )
    53.99 ( 7.004 )
    49.92 ( 22.128 )
        CD45+CD3+CD8-CD69+; D15; S2;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    66.87 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69+; D29; n=1,3,1,4,4,8
    59.17 ( 99999 )
    66.23 ( 5.538 )
    54.82 ( 99999 )
    57.72 ( 3.694 )
    59.41 ( 7.751 )
    50.71 ( 19.479 )
        CD45+CD3+CD8-CD69+; FU;n=1,2,0,3,1,4
    52.89 ( 99999 )
    65.54 ( 8.811 )
    99999 ( 99999 )
    62.68 ( 3.581 )
    64.72 ( 99999 )
    59.43 ( 17.448 )
        CD45+CD3+CD8-CD69+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    41.04 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD107+;D1pre; n=1,3,1,5,4,9
    1.89 ( 99999 )
    8.52 ( 6.264 )
    8.62 ( 99999 )
    9.13 ( 7.030 )
    9.40 ( 9.095 )
    8.89 ( 7.406 )
        CD45+CD3+CD8-CD107+;D1;1 h;n=1,3,1,5,4,9
    2.05 ( 99999 )
    9.13 ( 9.350 )
    0.00 ( 99999 )
    8.77 ( 6.304 )
    10.14 ( 11.064 )
    5.52 ( 3.023 )
        CD45+CD3+CD8-CD107+;D1;6 h;n=1,3,1,5,4,11
    4.79 ( 99999 )
    8.43 ( 6.165 )
    14.66 ( 99999 )
    10.25 ( 7.708 )
    11.10 ( 12.927 )
    8.49 ( 3.930 )
        CD45+CD3+CD8-CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    7.89 ( 99999 )
    22.06 ( 12.183 )
    99999 ( 99999 )
    12.25 ( 99999 )
        CD45+CD3+CD8-CD107+; D8; n=1,3,0,5,4,8
    16.59 ( 99999 )
    5.43 ( 4.942 )
    99999 ( 99999 )
    8.44 ( 5.762 )
    6.89 ( 3.550 )
    7.20 ( 3.406 )
        CD45+CD3+CD8-CD107+; D15; S1;n=1,3,1,5,4,9
    8.04 ( 99999 )
    4.31 ( 2.868 )
    67.24 ( 99999 )
    7.32 ( 4.700 )
    6.66 ( 4.113 )
    10.03 ( 7.687 )
        CD45+CD3+CD8-CD107+; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    79.79 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD107+; D29; n=1,3,1,4,4,8
    6.04 ( 99999 )
    5.33 ( 3.967 )
    45.69 ( 99999 )
    7.99 ( 2.600 )
    8.29 ( 3.475 )
    8.07 ( 5.728 )
        CD45+CD3+CD8-CD107+; FU;n=1,2,0,3,1,4
    3.99 ( 99999 )
    12.22 ( 14.015 )
    99999 ( 99999 )
    16.79 ( 8.978 )
    4.78 ( 99999 )
    16.10 ( 11.466 )
        CD45+CD3+CD8-CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    10.62 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69+CD107+;D1pre; n=1,3,1,5,4,9
    1.88 ( 99999 )
    8.34 ( 6.086 )
    8.62 ( 99999 )
    8.66 ( 6.705 )
    8.70 ( 8.036 )
    8.49 ( 7.511 )
        CD45+CD3+CD8-CD69+CD107+;D1;1 h;n=1,3,1,5,4,9
    2.03 ( 99999 )
    8.84 ( 8.957 )
    0.00 ( 99999 )
    8.39 ( 6.132 )
    9.37 ( 9.954 )
    5.08 ( 3.208 )
        CD45+CD3+CD8-CD69+CD107+;D1;6 h;n=1,3,1,5,4,11
    4.69 ( 99999 )
    7.99 ( 5.509 )
    14.66 ( 99999 )
    9.81 ( 7.518 )
    10.26 ( 11.433 )
    7.64 ( 3.879 )
        CD45+CD3+CD8-CD69+CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    7.89 ( 99999 )
    20.45 ( 10.684 )
    99999 ( 99999 )
    11.90 ( 99999 )
        CD45+CD3+CD8-CD69+CD107+; D8; n=1,3,0,5,4,8
    15.40 ( 99999 )
    5.16 ( 4.542 )
    99999 ( 99999 )
    8.22 ( 5.569 )
    6.68 ( 3.439 )
    6.35 ( 3.062 )
        CD45+CD3+CD8-CD69+CD107+; D15; S1;n=1,3,1,5,4,9
    7.37 ( 99999 )
    4.28 ( 2.851 )
    62.07 ( 99999 )
    7.09 ( 4.543 )
    6.42 ( 3.978 )
    9.27 ( 7.216 )
        CD45+CD3+CD8-CD69+CD107+; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    58.06 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69+CD107+; D29; n=1,3,1,4,4,8
    5.81 ( 99999 )
    5.26 ( 3.913 )
    38.58 ( 99999 )
    7.39 ( 1.938 )
    8.03 ( 3.389 )
    6.92 ( 4.718 )
        CD45+CD3+CD8-CD69+CD107+; FU;n=1,2,0,3,1,4
    3.94 ( 99999 )
    11.93 ( 13.598 )
    99999 ( 99999 )
    16.09 ( 8.306 )
    4.63 ( 99999 )
    14.87 ( 10.444 )
        CD45+CD3+CD8-CD69+CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    9.71 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69+CD107-;D1pre; n=1,3,1,5,4,9
    46.02 ( 99999 )
    52.84 ( 2.952 )
    55.17 ( 99999 )
    51.72 ( 7.637 )
    50.08 ( 9.719 )
    43.63 ( 15.780 )
        CD45+CD3+CD8-CD69+CD107-;D1;1 h;n=1,3,1,5,4,9
    47.12 ( 99999 )
    49.48 ( 3.288 )
    67.19 ( 99999 )
    52.53 ( 6.408 )
    49.68 ( 9.756 )
    46.78 ( 20.420 )
        CD45+CD3+CD8-CD69+CD107-;D1;6 h;n=1,3,1,5,4,11
    57.92 ( 99999 )
    52.25 ( 6.443 )
    62.93 ( 99999 )
    49.16 ( 4.649 )
    48.93 ( 11.819 )
    48.55 ( 16.115 )
        CD45+CD3+CD8-CD69+CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    59.21 ( 99999 )
    42.91 ( 5.515 )
    99999 ( 99999 )
    39.59 ( 99999 )
        CD45+CD3+CD8-CD69+CD107-; D8; n=1,3,0,5,4,8
    41.88 ( 99999 )
    51.21 ( 6.451 )
    99999 ( 99999 )
    53.19 ( 5.196 )
    57.91 ( 9.965 )
    36.45 ( 12.237 )
        CD45+CD3+CD8-CD69+CD107-; D15;S1; n=1,3,1,5,4,9
    40.25 ( 99999 )
    59.88 ( 3.546 )
    13.79 ( 99999 )
    54.48 ( 6.572 )
    47.58 ( 6.986 )
    40.65 ( 18.749 )
        CD45+CD3+CD8-CD69+CD107-; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    8.81 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69+CD107-; D29; n=1,3,1,4,4,8
    53.36 ( 99999 )
    60.98 ( 1.681 )
    16.24 ( 99999 )
    50.33 ( 5.623 )
    51.37 ( 5.812 )
    43.79 ( 19.299 )
        CD45+CD3+CD8-CD69+CD107-; FU;n=1,2,0,3,1,4
    48.95 ( 99999 )
    53.62 ( 4.794 )
    99999 ( 99999 )
    46.59 ( 4.968 )
    60.09 ( 99999 )
    44.55 ( 12.109 )
        CD45+CD3+CD8-CD69+CD107-; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    31.33 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69-CD107+;D1pre; n=1,3,1,5,4,9
    0.01 ( 99999 )
    0.17 ( 0.180 )
    0.00 ( 99999 )
    0.47 ( 0.607 )
    0.70 ( 1.089 )
    0.41 ( 0.541 )
        CD45+CD3+CD8-CD69-CD107+;D1;1 h;n=1,3,1,5,4,9
    0.03 ( 99999 )
    0.27 ( 0.414 )
    0.00 ( 99999 )
    0.38 ( 0.526 )
    0.77 ( 1.174 )
    0.43 ( 0.496 )
        CD45+CD3+CD8-CD69-CD107+;D1;6 h;n=1,3,1,5,4,11
    0.11 ( 99999 )
    0.44 ( 0.691 )
    0.00 ( 99999 )
    0.44 ( 0.695 )
    0.85 ( 1.537 )
    0.85 ( 1.277 )
        CD45+CD3+CD8-CD69-CD107+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    0.00 ( 99999 )
    1.62 ( 1.492 )
    99999 ( 99999 )
    0.35 ( 99999 )
        CD45+CD3+CD8-CD69-CD107+; D8; n=1,3,0,5,4,8
    1.19 ( 99999 )
    0.27 ( 0.406 )
    99999 ( 99999 )
    0.22 ( 0.239 )
    0.21 ( 0.194 )
    0.85 ( 0.855 )
        CD45+CD3+CD8-CD69-CD107+; D15;S1; n=1,3,1,5,4,9
    0.66 ( 99999 )
    0.02 ( 0.020 )
    5.17 ( 99999 )
    0.23 ( 0.217 )
    0.25 ( 0.179 )
    0.76 ( 0.966 )
        CD45+CD3+CD8-CD69-CD107+; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    21.74 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69-CD107+; D29; n=1,3,1,4,4,8
    0.24 ( 99999 )
    0.08 ( 0.057 )
    7.11 ( 99999 )
    0.60 ( 0.787 )
    0.23 ( 0.117 )
    1.15 ( 1.764 )
        CD45+CD3+CD8-CD69-CD107+; FU;n=1,2,0,3,1,4
    0.05 ( 99999 )
    0.30 ( 0.417 )
    99999 ( 99999 )
    0.70 ( 0.729 )
    0.15 ( 99999 )
    1.22 ( 1.319 )
        CD45+CD3+CD8-CD69-CD107+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    0.91 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69-CD107-;D1pre; n=1,3,1,5,4,9
    52.08 ( 99999 )
    38.64 ( 3.370 )
    36.21 ( 99999 )
    39.14 ( 9.186 )
    40.53 ( 9.843 )
    47.48 ( 19.639 )
        CD45+CD3+CD8-CD69-CD107-;D1;1 h;n=1,3,1,5,4,9
    50.83 ( 99999 )
    41.39 ( 6.239 )
    32.81 ( 99999 )
    38.69 ( 6.983 )
    40.19 ( 13.401 )
    47.70 ( 22.541 )
        CD45+CD3+CD8-CD69-CD107-;D1;6 h;n=1,3,1,5,4,11
    37.28 ( 99999 )
    39.32 ( 4.165 )
    22.41 ( 99999 )
    40.59 ( 6.401 )
    39.98 ( 14.362 )
    42.96 ( 17.217 )
        CD45+CD3+CD8-CD69-CD107-; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    32.89 ( 99999 )
    35.03 ( 6.661 )
    99999 ( 99999 )
    48.16 ( 99999 )
        CD45+CD3+CD8-CD69-CD107-; D8; n=1,3,0,5,4,8
    41.53 ( 99999 )
    43.36 ( 7.367 )
    99999 ( 99999 )
    38.37 ( 3.532 )
    35.20 ( 10.279 )
    56.36 ( 12.433 )
        CD45+CD3+CD8-CD69-CD107-; D15;S1;n=1,3,1,5,4,9
    51.72 ( 99999 )
    35.82 ( 6.285 )
    18.97 ( 99999 )
    38.20 ( 4.657 )
    45.76 ( 6.941 )
    49.32 ( 21.812 )
        CD45+CD3+CD8-CD69-CD107-; D15;S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    11.4 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3+CD8-CD69-CD107-; D29; n=1,3,1,4,4,8
    40.59 ( 99999 )
    33.69 ( 5.590 )
    38.07 ( 99999 )
    41.69 ( 3.048 )
    40.37 ( 7.766 )
    48.14 ( 18.661 )
        CD45+CD3+CD8-CD69-CD107-; FU;n=1,2,0,3,1,4
    47.06 ( 99999 )
    34.17 ( 9.228 )
    99999 ( 99999 )
    36.61 ( 4.300 )
    35.13 ( 99999 )
    39.35 ( 17.631 )
        CD45+CD3+CD8-CD69-CD107-; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    58.05 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD19+CD69+;D1pre; n=1,3,1,5,4,9
    75.76 ( 99999 )
    67.04 ( 8.518 )
    84.75 ( 99999 )
    70.41 ( 7.715 )
    66.51 ( 16.098 )
    60.06 ( 14.370 )
        CD45+CD3-CD19+CD69+;D1;1 h;n=1,3,1,5,4,9
    80.05 ( 99999 )
    66.03 ( 12.856 )
    100.00 ( 99999 )
    72.80 ( 9.542 )
    67.42 ( 15.190 )
    61.79 ( 14.941 )
        CD45+CD3-CD19+CD69+;D1;6 h;n=1,3,1,5,4,11
    78.69 ( 99999 )
    69.97 ( 8.412 )
    84.21 ( 99999 )
    68.55 ( 5.810 )
    63.22 ( 18.089 )
    66.22 ( 20.094 )
        CD45+CD3-CD19+CD69+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    100.00 ( 99999 )
    71.53 ( 0.721 )
    99999 ( 99999 )
    58.57 ( 99999 )
        CD45+CD3-CD19+CD69+; D8; n=1,3,0,5,4,8
    72.44 ( 99999 )
    62.85 ( 5.952 )
    99999 ( 99999 )
    70.60 ( 5.653 )
    66.95 ( 20.328 )
    52.90 ( 52.90 )
        CD45+CD3-CD19+CD69+; D15;S1; n=1,3,1,5,4,9
    71.85 ( 99999 )
    64.28 ( 7.449 )
    89.47 ( 99999 )
    70.07 ( 6.942 )
    61.50 ( 12.596 )
    61.77 ( 61.77 )
        CD45+CD3-CD19+CD69+; D15;S2;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    85.95 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD3-CD19+CD69+; D29; n=1,3,1,4,4,8
    74.65 ( 99999 )
    72.22 ( 17.828 )
    66.18 ( 99999 )
    68.83 ( 5.767 )
    65.80 ( 7.211 )
    61.49 ( 61.49 )
        CD45+CD3-CD19+CD69+; FU;n=1,2,0,3,1,4
    74.67 ( 99999 )
    68.44 ( 5.268 )
    99999 ( 99999 )
    73.60 ( 7.363 )
    73.22 ( 99999 )
    70.54 ( 70.54 )
        CD45+CD3-CD19+CD69+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    60.00 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD14+CD69+;D1pre; n=1,3,1,5,4,9
    99.66 ( 99999 )
    99.57 ( 0.371 )
    100.00 ( 99999 )
    99.27 ( 0.308 )
    99.19 ( 1.046 )
    99.39 ( 0.407 )
        CD45+CD14+CD69+;D1;1 h;n=1,3,1,5,4,9
    99.86 ( 99999 )
    99.54 ( 0.204 )
    99.55 ( 99999 )
    99.42 ( 0.202 )
    99.51 ( 0.658 )
    99.37 ( 0.725 )
        CD45+CD14+CD69+;D1;6 h;n=1,3,1,5,4,11
    99.45 ( 99999 )
    99.19 ( 0.239 )
    99.78 ( 99999 )
    99.28 ( 0.393 )
    99.11 ( 1.442 )
    99.24 ( 0.942 )
        CD45+CD14+CD69+; D2; n=0,0,1,2,0,1
    99999 ( 99999 )
    99999 ( 99999 )
    100.00 ( 99999 )
    99.16 ( 1.018 )
    99999 ( 99999 )
    99.06 ( 99999 )
        CD45+CD14+CD69+; D8; n=1,3,0,5,4,8
    99.41 ( 99999 )
    99.49 ( 0.297 )
    99999 ( 99999 )
    99.15 ( 0.763 )
    99.78 ( 0.241 )
    98.64 ( 1.993 )
        CD45+CD14+CD69+; D15; S1; n=1,3,1,5,4,9
    99.37 ( 99999 )
    99.70 ( 0.145 )
    100.00 ( 99999 )
    99.71 ( 0.311 )
    99.50 ( 0.435 )
    97.67 ( 3.444 )
        CD45+CD14+CD69+; D15; S2; n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    99.74 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
        CD45+CD14+CD69+; D29; n=1,3,1,4,4,8
    99.66 ( 99999 )
    99.61 ( 0.391 )
    98.85 ( 99999 )
    99.53 ( 0.379 )
    99.68 ( 0.225 )
    98.98 ( 1.950 )
        CD45+CD14+CD69+; FU;n=1,2,0,3,1,4
    99.71 ( 99999 )
    99.66 ( 0.028 )
    99999 ( 99999 )
    99.62 ( 0.219 )
    99.47 ( 99999 )
    99.65 ( 0.288 )
        CD45+CD14+CD69+; USC;n=0,0,1,0,0,0
    99999 ( 99999 )
    99999 ( 99999 )
    96.17 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    99999 ( 99999 )
    Notes
    [106] - PD Population
    [107] - PD Population
    [108] - PD Population
    [109] - PD Population
    [110] - PD Population
    [111] - PD Population
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).
    Adverse event reporting additional description
    AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    20.1
    Reporting groups
    Reporting group title
    GSK2849330 1.4 mg/kg weekly
    Reporting group description
    		 Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days

    Reporting group title
    GSK2849330 3 mg/kg every 2 weeks
    Reporting group description
    		 Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

    Reporting group title
    GSK2849330 3 mg/kg weekly
    Reporting group description
    		 Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.

    Reporting group title
    GSK2849330 10 mg/kg every 2 weeks
    Reporting group description
    		 Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

    Reporting group title
    GSK2849330 30 mg/kg every 2 weeks
    Reporting group description
    		 Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days

    Reporting group title
    GSK2849330 30 mg/kg weekly
    Reporting group description
    		 Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).

    Serious adverse events
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    1 / 4 (25.00%)
    3 / 14 (21.43%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    1
         number of deaths resulting from adverse events
    Investigations
    Ejection fraction decreased
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Melaena
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Escherichia sepsis
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Urosepsis
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 GSK2849330 1.4 mg/kg weekly GSK2849330 3 mg/kg every 2 weeks GSK2849330 3 mg/kg weekly GSK2849330 10 mg/kg every 2 weeks GSK2849330 30 mg/kg every 2 weeks GSK2849330 30 mg/kg weekly
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    1 / 1 (100.00%)
    3 / 3 (100.00%)
    2 / 2 (100.00%)
    5 / 5 (100.00%)
    4 / 4 (100.00%)
    14 / 14 (100.00%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    4
    Vena cava thrombosis
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 3 (66.67%)
    2 / 2 (100.00%)
    2 / 5 (40.00%)
    2 / 4 (50.00%)
    10 / 14 (71.43%)
         occurrences all number
    0
    2
    2
    2
    2
    12
    Non-cardiac chest pain
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    1 / 2 (50.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    2
    0
    1
    0
    Chest pain
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    Chills
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    Malaise
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    Oedema peripheral
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    Chest discomfort
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Discomfort
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Influenza like illness
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    1 / 2 (50.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    Mucosal inflammation
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Pain
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Pyrexia
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Reproductive system and breast disorders
    Vaginal haemorrhage
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Vulvovaginal pruritus
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    1 / 2 (50.00%)
    1 / 5 (20.00%)
    1 / 4 (25.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    1
    1
    1
    1
    2
    Pleural effusion
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    1 / 2 (50.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    Asthma
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Epistaxis
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Nasal congestion
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Pulmonary embolism
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Upper-airway cough syndrome
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Wheezing
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    1
    0
    0
    0
    2
    Product issues
    Device dislocation
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    2 / 5 (40.00%)
    0 / 4 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    0
    0
    2
    0
    4
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    3 / 14 (21.43%)
         occurrences all number
    0
    0
    0
    1
    0
    4
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    1 / 2 (50.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    4 / 14 (28.57%)
         occurrences all number
    0
    0
    1
    0
    0
    4
    Weight decreased
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    4 / 14 (28.57%)
         occurrences all number
    0
    0
    0
    0
    0
    5
    Blood alkaline phosphatase increased
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    3 / 14 (21.43%)
         occurrences all number
    0
    0
    0
    0
    1
    3
    Blood bilirubin increased
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Injury, poisoning and procedural complications
    Infusion related reaction
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    1 / 2 (50.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    0
    1
    0
    0
    2
    Thermal burn
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Cardiac disorders
    Aortic valve disease
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 3 (66.67%)
    2 / 2 (100.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    3
    3
    2
    0
    2
    Dizziness
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    Dysgeusia
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    Paraesthesia
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Peripheral sensory neuropathy
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Tremor
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Cough
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    0
    0
    1
    1
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    3 / 14 (21.43%)
         occurrences all number
    0
    0
    0
    0
    1
    3
    Eye disorders
    Vision blurred
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    1 / 2 (50.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    Glaucoma
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Retinal haemorrhage
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    1 / 1 (100.00%)
    3 / 3 (100.00%)
    1 / 2 (50.00%)
    2 / 5 (40.00%)
    3 / 4 (75.00%)
    9 / 14 (64.29%)
         occurrences all number
    1
    4
    3
    2
    4
    12
    Abdominal pain
         subjects affected / exposed
    0 / 1 (0.00%)
    2 / 3 (66.67%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    4 / 14 (28.57%)
         occurrences all number
    0
    2
    0
    0
    0
    7
    Nausea
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    1 / 2 (50.00%)
    2 / 5 (40.00%)
    0 / 4 (0.00%)
    4 / 14 (28.57%)
         occurrences all number
    0
    0
    2
    2
    0
    4
    Vomiting
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    1 / 2 (50.00%)
    0 / 5 (0.00%)
    3 / 4 (75.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    1
    0
    4
    2
    Constipation
         subjects affected / exposed
    1 / 1 (100.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    2 / 14 (14.29%)
         occurrences all number
    1
    0
    0
    0
    1
    3
    Abdominal discomfort
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    1
    3
    Abdominal distension
         subjects affected / exposed
    1 / 1 (100.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    1
    0
    0
    1
    0
    Abdominal pain upper
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    0
    1
    0
    1
    Abdominal pain lower
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    2 / 4 (50.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    Dry mouth
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    Oesophageal obstruction
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    Ascites
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Dyspepsia
         subjects affected / exposed
    1 / 1 (100.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Gingival pain
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Impaired gastric emptying
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Mouth ulceration
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Oral pain
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Stomatitis
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Tongue coated
         subjects affected / exposed
    1 / 1 (100.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    1 / 2 (50.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    0
    4
    0
    0
    2
    Dry skin
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    1 / 4 (25.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    0
    1
    1
    1
    Rash
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    Rash maculo-papular
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    Skin fissures
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    Blister
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Dermatitis acneiform
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Onychomadesis
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Psoriasis
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Rash macular
         subjects affected / exposed
    1 / 1 (100.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    Skin hyperpigmentation
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Skin ulcer
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Musculoskeletal and connective tissue disorders
    Myalgia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    1 / 2 (50.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    1
    1
    0
    1
    4
    Back pain
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    1 / 4 (25.00%)
    3 / 14 (21.43%)
         occurrences all number
    0
    0
    0
    1
    1
    3
    Arthralgia
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    Flank pain
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0
    Musculoskeletal pain
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    Groin pain
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Muscle twitching
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Muscular weakness
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Musculoskeletal chest pain
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Neck pain
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Pain in extremity
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Infections and infestations
    Lung infection
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    Cystitis
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Oral candidiasis
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Otitis externa
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Paronychia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Respiratory tract infection
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Urinary tract infection
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Viral infection
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    1 / 5 (20.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    1 / 2 (50.00%)
    2 / 5 (40.00%)
    2 / 4 (50.00%)
    3 / 14 (21.43%)
         occurrences all number
    0
    1
    1
    2
    2
    3
    Hypomagnesaemia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    0
    0
    1
    1
    Hypoalbuminaemia
         subjects affected / exposed
    0 / 1 (0.00%)
    0 / 3 (0.00%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    1 / 4 (25.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Hypokalaemia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Hypophagia
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Increased appetite
         subjects affected / exposed
    0 / 1 (0.00%)
    1 / 3 (33.33%)
    0 / 2 (0.00%)
    0 / 5 (0.00%)
    0 / 4 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    10 Sep 2014
    Four molecularly-defined, tumor histology groups were added for study during Part 2. Additional inclusion criteria for participants in Part 2 were added to clarify the number of prior lines of therapy allowed for study entry and to require participants to undergo pre and on-treatment tumor biopsies. References to cohorts of participants in Part 2 were removed and replaced with groups of participants. An additional cohort of participants was added to Part 1. This cohort will receive weekly treatment with 30 milligrams per kilogram (mg/kg) GSK2849330, with an option to reduce dosing frequency to every 2 weeks after 24 weeks. The approximate number of participants in Part 1 was changed from 10 to 13, to accommodate the additional weekly cohort. The anticipated number of participants in Part 1 is now 34. The rationale for adding a weekly dosing regimen was added. The exclusion criteria for participants with untreated brain or meningeal metastases and participants treated for stable brain metastases were clarified. PK sampling times were revised for participants in Part 1 enrolled under this amendment and for participants enrolled in Part 2. Preclinical and nonclinical findings on HER3 antibodies from recent studies and abstracts were added, including the rationale for the tumor types selected for Part 2. The predicted half-life of GSK2849330 was changed from 8-9 days to 7 days at 30 mg/kg. The expected dosing frequency was changed from >=2 weeks to 1-2 weeks. Preliminary noncompartmental and population PK parameters for the 1.4 mg/kg, 3 mg/kg, and 10 mg/kg doses were added. Permitted and prohibited medications (growth factors, anticoagulants, and corticosteroids) were clarified. The recommendations for management of diarrhea were expanded. The requirement for a sample for selected cytokines in participants experiencing suspected infusion-related reactions was added. The criterion for withholding of study treatment for QTc prolongation was clarified.
    09 Jan 2015
    The inclusion criteria were modified for Molecularly Defined Tumor Histology Groups 1, 2 and 4 in Part 2 to remove the statement that participants would be eligible for inclusion into the study if they had not received standard therapy when such therapy was not available to them commercially or via a clinical trial. The definition of DLT for participants with thrombocytopenia was expanded to include Grade 3 events of thrombocytopenia associated with bleeding in addition to all Grade 4 events. The statements regarding obtaining paired tumor biopsies have been modified to include that all biopsies should be obtained from tumor easily accessible to biopsy using a procedure that is safe for the participant. The total volume of blood to be collected within the first 30 days of participation has been modified to account for the increased PK sampling. Inconsistencies were corrected in the Time and Events Tables in Section 7. Minor grammatical and formatting changes were made throughout the document.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 08:19:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA